GLOBAL DIABETES COMPACT FORUM

FIRST MEETING
NOVEMBER 10TH AND 11TH, 2021
PARTICIPANT PROFILES
<table>
<thead>
<tr>
<th></th>
<th>Organization Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>All India Institute of Medical Sciences</td>
</tr>
<tr>
<td>2.</td>
<td>Associação de Diabetes Juvenil (ADJ - Diabetes Brasil)</td>
</tr>
<tr>
<td>3.</td>
<td>Beta Cell Foundation</td>
</tr>
<tr>
<td>4.</td>
<td>Blue Circle Diabetes Foundation</td>
</tr>
<tr>
<td>5.</td>
<td>Centre for Chronic Disease Control (CCDC)</td>
</tr>
<tr>
<td>6.</td>
<td>CNS (Citizen News Service)</td>
</tr>
<tr>
<td>7.</td>
<td>Deakin University - The Global Obesity Centre</td>
</tr>
<tr>
<td>8.</td>
<td>Diabesties Foundation</td>
</tr>
<tr>
<td>9.</td>
<td>Diabetes Australia</td>
</tr>
<tr>
<td>10.</td>
<td>Diabetes Canada</td>
</tr>
<tr>
<td>11.</td>
<td>Diabetes Awareness Association - Malawi</td>
</tr>
<tr>
<td>12.</td>
<td>Empower India</td>
</tr>
<tr>
<td>13.</td>
<td>European Diabetes Forum (EUDF)</td>
</tr>
<tr>
<td>14.</td>
<td>Foundation for Innovative New Diagnostics (FIND)</td>
</tr>
<tr>
<td>15.</td>
<td>Grand Challenges Canada</td>
</tr>
<tr>
<td>16.</td>
<td>Health Finance Institute</td>
</tr>
<tr>
<td>17.</td>
<td>International Alliance for Diabetes Action (IADA)</td>
</tr>
<tr>
<td>18.</td>
<td>International Alliance of Patient Organizations</td>
</tr>
<tr>
<td>19.</td>
<td>International Diabetes Federation</td>
</tr>
<tr>
<td>20.</td>
<td>International Diabetes Federation - Europe Region</td>
</tr>
<tr>
<td>21.</td>
<td>International Diabetes Federation - South America and Central America Region</td>
</tr>
<tr>
<td>22.</td>
<td>International Federation of Pharmaceutical Manufacturers &amp; Associations (IFPMA)</td>
</tr>
<tr>
<td>23.</td>
<td>International Generic and Biosimilar Medicines Association (IGBA)</td>
</tr>
<tr>
<td>24.</td>
<td>International Rescue Committee</td>
</tr>
<tr>
<td>25.</td>
<td>JDRF International</td>
</tr>
<tr>
<td>26.</td>
<td>Landmark Group</td>
</tr>
<tr>
<td>27.</td>
<td>London School of Hygiene and Tropical Medicine – Centre for Global Chronic Conditions</td>
</tr>
<tr>
<td>28.</td>
<td>Medecins Sans Frontières</td>
</tr>
<tr>
<td>29.</td>
<td>Medicines Patent Pool</td>
</tr>
<tr>
<td>30.</td>
<td>NCD Alliance</td>
</tr>
</tbody>
</table>
31. NCD Child
32. NGO Santé Diabète (Association Santé Diabète)
33. PATH
34. Positive on Glucose – Lebanon
35. Primary Care International
36. Semmelweis University Diabetes Dental Research Group
37. South Africa Public Health and Preventative Medicine Association
38. Staffordshire University
39. Stitching Health Action International
40. Sweet Life Diabetes Community – South Africa
41. T1International
42. Unit of Therapeutic Patient Education, University Hospitals of Geneva (HUG)
43. University of Pretoria, South Africa, Department of Public Medicine
44. WHO Collaborating Centre - Diabetic Association of Pakistan
45. WHO-collaborating Centre - Prof M Viswanathan Diabetes Research Centre & M V Hospital for Diabetes Pvt Ltd. – Chennai India
46. WHO Collaborating Centre - Tehran University of Medical Sciences - Endocrinology and Metabolism Research Institute
47. WHO-collaborating Centre for Diabetes Treatment and Education, National Hospital Organization, Kyoto Medical Center, Japan
48. World Diabetes Foundation
49. World Heart Federation

**Notes**

Applicants submitted information two weeks or sooner before Forum meeting may not be included in this document. Responses from invitees are verbatim, with only light editing for spelling mistakes or formatting.
What is the mission of your organization?
Research, Teaching, Health services

Describe the type of work your organization/entity does in the field of diabetes:
Department of Community & Family Medicine, All India Institute of Medical Sciences, Gorakhpur deals with Health promotion, prevention, curative and rehabilitation services of Diabetes and other non-communicable disease.

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
It will help us to actively involved in primary healthcare services at community level and may help us in guiding better transition of care from primary to tertiary care of diabetes patients by involving the family members.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
No information given.

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy
No information given.

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation
No information given.

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?
No information given.
What is the mission of your organization?
To advocate for, defend social rights, inform and educate people with diabetes, family members and health workers, prioritizing those in social vulnerability, to guarantee access to quality care, prevent complications and favor quality of life.

Describe the type of work your organization/ entity does in the field of diabetes:
ADJ Diabetes Brasil was founded in 1980 by a group of parents of children and adolescents with diabetes, who understood the importance of diabetes education as a way to allow their children to be healthy and have their short and long term quality of life preserved. It is a nongovernmental, non-profit organization that focuses its activities on the awareness and education of people with (and without) about diabetes, training health professionals and advocating for better health and social programs and policies, as well as defending social rights of the Brazilian people. During its 41 years of existence, ADJ became the largest diabetes association in the country, with 30+ other associations affiliated to it, and a reference in health and social transformation in Brazil, through its partnerships with the different sectors and as a full member of municipal, state and federal level committees and working groups representing the civil society before the public sector. ADJ has always joined efforts with international organizations, serving as a reference in the Latin American region. Still in the 1980’s ADJ joined the Juvenile Diabetes Research Foundation (JDRF), with whom ADJ currently has an active MoU, and later, in the 1990’s it joined the International Diabetes Federation (IDF), the largest global diabetes entity, where ADJ is a key partner with strategic roles (such as co-developing and testing the world wide successful package KiDS).

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
ADJ Diabetes Brasil hopes to contribute with its large experience to build a robust WHO Global Diabetes Compact, with realistic targets and effectively implementable strategies, in order to improve significantly diabetes care and outcomes worldwide.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
ADJ has had key role for the full coverage of diabetes care in Brazil and is currently engaged in the Insulin Working Group of the Ministry of Health, with the Brazilian Diabetes Medical Society, Legislators and the Brazilian Diabetes Federation with the goal of optimizing access to insulin, technologies and quality care in the entire country. Additionally, it has been collaborating with organizations in neighbour countries sharing its best practices to achieve such coverage and
Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy.

ADJ is currently offering an "Educating the Educators" course, to build capacity of health professionals in the different regions of the country to improve diabetes care (https://adj.org.br/2021/10/22/40a-edicao-do-curso-de-qualificacao-em-educacao-em-diabetes-para-profissionais-de-saude-e-umsucesso/).

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation

ADJ has served as a partner to different universities and research instituted to advance science, especially on diabetes care, treatment and education in Brazil.

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?

Yes, we have received many complaints regarding shortage of medicines and lack of access to healthcare professionals during the pandemic. ADJ has promptly organized a free of charge teleconsultation service to assist this population and advocated to make sure that the medicines and supplies were quickly made available again. More details on:

https://doi.org/10.1016/j.dsx.2020.10.005
https://doi.org/10.1016/j.diabres.2020.108304
https://doi.org/10.1016/j.diabres.2020.108301

Participant Profile – Beta Cell Foundation – USA

Website: https://betacellfoundation.org

What is the mission of your organization?

The Beta Cell Foundation fosters and funds grassroots projects developed by individuals living with type 1 diabetes to educate, empower, and unite our community.

Describe the type of work your organization/ entity does in the field of diabetes:

The Beta Cell Foundation funds and supports grassroots projects developed and run by people living with diabetes to help educate and empower others in the community. We host a public calendar of T1D meetups (local and virtual) for people to find community; we have management and advocacy resources written by people with T1D and informed by surveys (including one
on COVID-19 vaccine side effects that has been well cited); we host free webinars with T1D healthcare professionals; and we are developing three mobile apps: a social network to help people find local communities, a daily journal to help mental wellbeing, and an interactive diabetes simulator.

**What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?**

Too much diabetes policy, education, and research is not focused on patient needs, driven instead by the objectives of non-T1D actors and corporate sponsors. As an organization built by a diverse group of people living with type 1 diabetes and whose goal is to empower more patient voices, we hope to be able to bring our unique and impartial perspectives and experiences to The WHO Global Diabetes Compact Forum in order to improve outcomes for the vast majority of patients who are not currently represented.

**Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.**

We have advocacy materials on our website related to insulin access: [https://betacellfoundation.org/resources/advocacy/](https://betacellfoundation.org/resources/advocacy/)

**Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy.**

We have management materials on our website that address health literacy, [https://betacellfoundation.org/resources/management](https://betacellfoundation.org/resources/management) and are currently developing a mobile app that lets users simulation different situations with type 1 diabetes, teaching them about the disease and allowing them to “test” their knowledge.

**Please share any news, work, or events your organization is doing or plans to do regarding research and innovation**

We develop and share surveys with the community about various aspects of living with type 1 diabetes, such as COVID-19 side effects, mensuration and diabetes, and mental health and diabetes.

**Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?**

Many people with represent have been impacted by COVID-19. Some members have gotten sick and have had to navigate managing diabetes and COVID-19. Some have had to tackle the fear of getting sick and the isolation of needing to keep themselves safe while they see others out and living their lives normally. Some have expressed trepidation on side effects from vaccines and others have experiences very negative side effects. Others have had to physically go to doctors offices in order to get refills on insulin and other diabetes supplies, potentially putting themselves
What is the mission of your organization?
To educate, engage and empower people living with all types of diabetes (in India)

Describe the type of work your organization/ entity does in the field of diabetes:
Blue Circle Diabetes Foundation is a volunteer-led, registered non profit organisation that works in diabetes awareness and advocacy across India. It is the largest patient-led diabetes community & support group in India that welcomes people with type 1 diabetes, type 2 diabetes, gestational diabetes, etc. We are a 12A and 80G certified NGO.

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
We would like to scale up our advocacy and work in the diabetes space in India by working with the WHO's Global Diabetes Compact

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
Our Facebook community recently got selected to to the Facebook Accelerator Programme, with access to funding and mentorship. We are also in early stages of working with the State Government (of Maharashtra) regarding diabetes awareness, access to resources (insulin etc) and care

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy
None supplied

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation
None supplied

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?
During the Covid lockdown, access to supplies (insulins, CGMs, etc) was impacted and these were unavailable or hard to get. Our NGO liaised with local officials to ensure a smooth delivery to people with diabetes.
We understand Covid can create and exacerbate distress and common mental health issues like depression and anxiety. The Buddy Project Helpline is India’s first psychosocial diabetes and mental health helpline exclusively for people with all types of diabetes and their families. We are a volunteer-led, app-based multilingual, free helpline run by people with diabetes and caregivers who have been trained by the Centre for Mental Health Law & Policy, Indian Law Society, Pune and Chellaram Diabetes Institute, Pune in providing basic psychosocial and diabetes support. Our volunteers are fluent in English, Hindi, Dutch, Marathi, Bengali, Gujarati, and Punjabi.

**Participant Profile – Centre for Chronic Disease Control (CCDC)**

**Website:** https://ccdcindia.org/

**What is the mission of your organization?**

The mission of CCDC is primarily intended to address the growing challenge of chronic diseases, in varied settings of the developing countries through:

- Knowledge generation, which can inform policies and empower programmes for the prevention and control of chronic diseases; and
- Knowledge translation intended to operationalize research results by bridging the critical gaps between relevant research and effective implementation, through analytic work, capacity building, advocacy, and development of educational resources for enhancing the empowerment of people and professionals.

**Describe the type of work your organization/entity does in the field of diabetes:**

CCDC undertakes clinical research with special emphasis on chronic non-communicable diseases (NCD). Within the spectrum of chronic diseases, our main focus areas are: cardiology, diabetes and metabolic disease, vascular diseases, cancers, mental and oral health. Our research work has produced major insights into the epidemiology, developmental origin, and biomarkers of CVD and diabetes in India. Several studies have evaluated a range of biomarkers, performed exploratory metabolomic analysis, and created a substantial biorepository for future analyses. Our research is also directed on development, implementation, and evaluation of low-cost innovative interventions for primary and secondary prevention of common cardio-metabolic diseases to strengthen the health systems in resource-constrained settings. These strategies include but are not restricted to task shifting to nonphysician health care providers, decision support software, clinic flow modifications and opportunistic screening.

**What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?**

The WHO Global Diabetes Compact Forum will help foster partnerships between different
What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?

The WHO Global Diabetes Compact Forum will help foster partnerships between different stakeholders, ensuring commitment to work together and mobilize support to better equip health systems in tackling the diabetes epidemic. The forum will also serve as a platform to bring together experts to identify and evaluate ongoing initiatives in diabetes across the globe and scale up the ones with greater potential. Additionally, our membership will enable us to align our research goals and activities with those of the Forum and respond to the increasing burden of diabetes around the world is so deeply relevant to us and we will like to contribute towards achieving those aspirational goals. Also translating the mandate of Global Diabetes Compact Forum is so key to enhance the outcomes on every other goal and target of SDGs for each and every member state.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.

One of our ongoing studies aims to adapt, implement, and evaluate an IT-enabled platform for integrated tracking, referral, electronic decision support, and care coordination (ITREC) to treat hypertension and diabetes in rural communities that rely on the public healthcare system using mixed methods approach. This implementation research is intended to provide evidence of workable interventions to manage chronic diseases in India. This would inform the evolving National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular diseases and Stroke (NPCDCS) in India.

CCDC has also customized its copyrighted mPower Heart Software (CARDIOMETCARE-m) for the use at NCD clinics and has established a bigdata analytic capability for hypertension and diabetes care delivery. The “mPower Heart Software” is an Android-based electronic Clinical Decision Support System, and some of its major capabilities are: ability to identify patients with high risk for diabetes, hypertension or cardiovascular disease (CVD); ability to generate lifestyle intervention tailored to individual patients, ability to generate customized prescription for diabetes, hypertension, dyslipidemia and secondary prevention for CVD in accordance with the latest clinical management guidelines; ability to store and integrate longitudinal health records of the patients both locally in the android app and central server; and ability to work in the offline mode (without internet connectivity).

One of our previous works has evaluated the effect of a multi component quality improvement strategy that comprised of non-physician care coordinators and decision-support electronic health records on cardio metabolic profiles in patients with poorly controlled diabetes.
Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy

The clinical trials unit has developed a yoga-based program to prevent Type 2 DM among high-risk people in India and compare it’s effectiveness to enhanced standard care.

We have also conducted a trial to determine whether a resource- and culturally appropriate lifestyle intervention program in South Asian countries, provided to women with gestational diabetes (GDM) after delivery, will reduce the incidence of type 2 diabetes, in a manner that is affordable, acceptable and scalable. The intervention comprised of a low-intensity lifestyle modification program delivered as four face-to-face group sessions combined with remote ongoing support, and an intensification offering when needed. A similar lifestyle-based intervention study is being conducted among employees in the organized sector with prediabetes or unmedicated diabetes in India. At each worksite groups of 10-12 people are paired with one trained lay educator and a professional health educator who deliver health education with a focus on teaching healthy behaviors, providing support, and facilitating group interactions.

In addition to diabetes related studies, CCDC has undertaken numerous other studies with a focus on prevention of cardio-vascular diseases and health promotion. CCDC has also established a network of primary care physicians and conducts regular capacity building programs in collaboration with experts across India. Several state Governments nominate government-affiliated participants across various health facilities to enroll for the course.

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation

Currently, there are more than twenty research initiatives funded by both national and international agencies, in progress at CCDC including those mentioned above. The team at CCDC is responsible for conceptualising research ideas, developing proposals and implementing the same on ground. Results from these have been published in peer-reviewed journals, received media coverage, disseminated at national and international platforms and often used for advocacy and to guide policy documents. We are sharing some of our other ongoing research initiatives:

Clinical Trials

- Yoga-CaRe: Yoga-based cardiac rehabilitation programme (Yoga-CaRe)
- Piloting of a Community Health Workers (CHWs) led Chronic Obstructive Pulmonary Disease (COPD) Management and Control Program in Rural India Epidemiology
- Strengthening evidence-based advocacy for influenza prevention and control in India
- Public Health Initiative on LMIC Air Pollution (PHILAP)
- Air Pollution and Health GEOHealth Hub Research and Capacity Building Program
Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?

The ongoing pandemic of SARS-CoV-2 has disproportionately affected older age groups and those with co-morbidities. While several studies have reported a high risk for severe infection and mortality associated with SARS-CoV-2 infection among people with hypertension and diabetes, little or no studies are on susceptibility of infection among this vulnerable population. In this context, we designed a survey in two of our pre-existing community cohorts for cardio-vascular diseases, established in urban and rural areas of Delhi NCR. The study intends to estimate and compare sero-prevalence of SARS-CoV-2 among people with and without diabetes and/or hypertension. The study will also explore the knowledge, attitude and health seeking behaviour of people and their impact on disease management and control with diabetes and/or hypertension during the pandemic. The proposed study will generate useful information on the co-occurrence and interaction of SARS-CoV-2 and noncommunicable diseases and help to plan testing,
What is the mission of your organization?
Vision: A just social order by achieving development justice for all (health, gender, economic, re-distributive, social and climate justice)
Mission: We work towards enhancing visibility of neglected issues related to development justice, in particular, health and gender, by documenting voices of key affected populations, among other constituencies, in our rights- and evidence-based thematic news coverage, and syndicating these news-feature articles to a range of print, online and social media advocating and campaigning for policy, programmatic and social changes to achieve development justice for all

Describe the type of work your organization/ entity does in the field of diabetes:
https://www.citizen-news.org/search/label/diabetes

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
Please see CNS vision and mission, each point of the mandate of Global Diabetes Compact Forum is so deeply relevant to us and we will like to contribute towards achieving those aspirational goals. Also translating the mandate of Global Diabetes Compact Forum is so key to enhance the outcomes on every other goal and target of SDGs for each and every member state.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
https://www.citizen-news.org/search/label/diabetes

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy
We keep diabetes on our radar 365 days! If you see what we do, you will find every day is World Diabetes Day since our foundation in 1991 where we began with tobacco control but soon the interlinkages of tobacco use and diabetes, brought us to the realisation of importance of including diabetes in everything we do.
Please share any news, work, or events your organization is doing or plans to do regarding research and innovation

We are not a research organization but we do our two bits to enhance communications around research we find important (also related to diabetes).

https://www.citizen-news.org/search/label/diabetes

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?

YES most certainly. When the Covid pandemic related steps were taken in Thailand and India, from the lockdown onwards there were serious problems people with diabetes faced in accessing services - essential lifesaving services - not just for diabetes but also for related co-morbidities and conditions (such as HIV, TB).

Even in 2021 lockdown, biggest government run hospitals, Super specialty hospitals and healthcare facilities were converted into 100% Covid hospitals - which was an important step to respond to Covid but also a major blow to all non-Covid health priorities that slipped off track. A recent white paper released by FICCI (Federation of Indian Chambers of Commerce & Industry) stated that due to Covid pandemic impact on our health system, India can expect 20% increase in TB deaths, 10% increase in HIV deaths, and over 2.2 million children will be dealing with vaccine preventable illnesses due to jeopardised routine immunisation programme during lockdowns.

Whether it is TB or HIV or other NCDs, we all know the deep association it has to diabetes. Probably community-led qualitative data (data with a soul) and quantitative data will provide more evidence on more impact of Covid response and how it has pushed us backwards by years/decades - reversed progress made on other SDGs.

It is high time to recognise the importance of integrated health responses, vital significance of universal healthcare (and not just universal health coverage), and recognise fundamental human right to health for every person on the planet - as health is so central to economy and every other SDGs to which all of our governments have committed themselves to, and rightly so. Clock is ticking so we have no choice but to act, and act fast - as price of inaction or not acting strong enough is too high.
What is the mission of your organization?
To catalyse improvements in population health, with a focus on obesity, through innovative research that empowers people and enables healthier environments.

Describe the type of work your organization/entity does in the field of diabetes:
- Conduct innovative population-level research on obesity prevention
- Advocate for evidence-based population health and obesity prevention policy
- Strengthen the skills of communities, professionals and academics in the science of obesity prevention through the life-course

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
Sharing and advocating for innovative research that empowers people and enables healthier environments for diabetes prevention

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
No information given.

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy.
Community based systems approaches for obesity prevention

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation
Intervention designs and evaluation tools for obesity prevention

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?
No information given.
What is the mission of your organization?
The Diabesties Foundation is a not-for-profit organization dedicated to serving the healthcare sector. We are actively involved in creating Diabetes Awareness and spreading Type 1 Diabetes Education to Indian society at large. We believe that healthcare is a fundamental right as well as duty of every Indian. From healthcare providers to family, friends and relatives, our mission is to cater to all the stakeholders involved in this journey. We also work predominantly for Awareness, Advocacy and Access. Diabesties is a movement dedicated to making every individual living with Type 1 Diabetes, feel heard, understood, supported, loved and celebrated.

Describe the type of work your organization/ entity does in the field of diabetes:
Our projects are under three wide categories: Awareness/Access, Education and Support. We believe that access to quality diabetes education is equally important to access to care. In India, we face unique challenges that make living with Type 1 Diabetes, slightly more challenging. Right from disturbing myths and taboos, to false promises of cures, from misdiagnosis to lack of access to insulin - we have witnessed heartbreaking stories of people living with this condition. We do not have a 360 degree Type 1 Diabetes support system in our country, as our health sector is already overburdened - people with T1D often have to figure out the technicalities about their condition by themselves and failing to do so, sometimes results in unfavourable situations. We want to bridge the gap between the Doctors and the people living with T1D - by making education a fundamental part of diabetes management.

In the times of covid 19 - data suggests that those with T1D fall under a vulnerable risk group - and we have tried to persist through the pandemic by offering educational, mental and social support. We also have been actively working with national bodies such as RSSDI, Diabetes India and the NHS to provide factual data, insulin and support to those in the rural sectors.

A few selected projects:
1. DiaMeet: While living with a chronic condition, one of the most important aspects of a healthy mind is Peer support. Therefore, DiaMEETS are our peer support parties - where T1D's and their families celebrate living with this condition, with games, conversations and lots of dancing! Questions are answered from lived experiences and its a beautiful showcase of support and camaraderie.

(https://www.youtube.com/watch?v=9ztceNMYkRw)
2. DTour: a National School programme focused on spreading awareness about Diabetes, the
difference in the types, and discuss stigmas and taboos.
3. One Drive: Sugar-testing camp in schools and NGO’s
(https://www.youtube.com/watch?v=GMw68tKjelQ&t=6s)
4. Mishti: Pledge Insulin, Gift A Life: Our goal is to ensure that no child in India should die or face
complications due to the lack of insulin and education
(https://www.youtube.com/watch?v=IYHtJwHAvUI)
5. Kiran: Project Kiran understands the importance of diabetes education being fundamental
to ones quality of life. We also understand that not all children learn alike. KIRAN has several
modules, games, instructions, manuals and lesson plans to cater to every Childs learning needs
and ensure quality education. (https://www.d1abesties.com/kiran)
6. T1D Comic: We believe in making T1D Education fun and engaging. Our comic series discusses
important aspects of T1D management with colourful illustrations, humour and relatable stories.
(https://www.d1abesties.com/comic)
7. DiaBIKE: a community project to explore your cities, spread awareness about T1D and also
understand the importance exercise in diabetes management.
8. Language Matters: A guide to sensitize HCPs and other caregivers with regards communication
in T1D. In collaboration with NHS UK (https://www.d1abesties.com/languagematters)

What does your organization hope to achieve through participation in the WHO Global
Diabetes Compact Forum?
We want to be able to collaborate and learn from other quality works and projects and
ensure that we can attain a sustainable and meaningful change. We would also like to use this
opportunity to work at a policy level to ensure that access to insulin is given importance.

Please share any news, work, or events your organization is doing or plans to do regarding
access to insulin and health technologies associated with diabetes.
Project Mishti is an effort to find pledgers to support children under poverty line with access to
insulin. We constantly do “madhumeets” a project to educate about newer tech.

Please share any news, work, or events your organization is doing or plans to do regarding
prevention, health promotion and health literacy
Our DTour project - is an awareness drive campaign to bring diabetes awareness into schools.
November - we are launching a huge awareness drive in collaboration with the Rotaract to spread
diabetes awareness at large.

Please share any news, work, or events your organization is doing or plans to do regarding
research and innovation
No information given.
Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?

During the first wave, with an understandable level of panic and fear, The Diabesties Foundation in collaboration with NHS UK and Diabetes India worked on and launched “Language Matters in times of Covid 19”. A guide to ease the panic and pass on credible information. Since a lot of talk on mortality rates of those with diabetes as a co-morbidity was in the press, we decided to create a document that would aid with reliable sources and advise. The document was worked on by people living with Diabetes and Health Care Professionals and was launch jointly in India and the UK.

During Covid - since face-to-face consultations were physically not possible - we launched the B2B project. Back to Basics is an education project by Diabesties. We understand the importance of one-on-one time and attention. Our B2B Team comprises of a panel of Diabetes Educators, Health Care Professionals, Mental Health experts and people living with over 10 years of experience. We have since, scheduled over 400 calls regarding Covid Stress, diabetes burnout and basic diabetes education.

We continue our efforts for education during these times. We went completely online and have facilitated several interactive sessions spanning topics from Diabetes Management to Covid burnout.

Covid Timeouts: For the last year, the only thing people can talk about is the pandemic. We are all so overwhelmed with news, information and statistics - that it weighs down on our mental health. Our “Covid Time-Outs” are brief slots where we don’t talk about covid at all. It gives everyone a mental breather.

We have also partnered with organisations to provide over 300 children with free insulin.
What is the mission of your organization?
Diabetes Australia was established in 1984 and is the national body for people affected by all types of diabetes and those at risk. Through leadership, prevention, management and research, Diabetes Australia is committed to reducing the impact of diabetes. We work in partnership with diabetes health professionals and educators, researchers and healthcare providers to minimise the impact of diabetes on the Australian community.

Describe the type of work your organization/entity does in the field of diabetes:
Diabetes Australia is a respected and valued source of information, advice and views utilised by government and the community. Our credibility and independence as a national voice allows us to translate knowledge and evidence into advocacy and programs for diabetes. Through leadership, prevention, management and research, Diabetes Australia is committed to reducing the impact of diabetes. We work in the spirit of collaboration and co-operation. We offer strong leadership, governance and finances for our programs and our member organisations. As leaders, we assist with administering the NDSS and advocate on issues impacting diabetes in Australia. As a trusted source of information, we offer advice on prevention and management. As a strong supporter of research, we work to develop the field of diabetes research through providing funding towards the prevention, management and cure for diabetes. Diabetes Australia works to raise the awareness about the seriousness of diabetes, promoting prevention and early detection strategies and advocating for better standards of care. Diabetes Australia is also a significant financial contributor to research into better treatments for diabetes and the search for a cure.

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
Diabetes Australia would like to participate in advocacy efforts to raise awareness of diabetes and increase support for the need for access to diabetes healthcare, education, medication and supplies.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
In Australia, insulin is covered as part of the Pharmaceutical Benefits Scheme and the price is set at AUD$41.30 (or AUD$6.60 for low-income healthcare card holders). An insulin prescription is generally 5 x 10ml vials, or 5 x 5 x 5ml penfills/disposable pens. Through the National Diabetes Services Scheme (NDSS), diabetes consumables (blood glucose strips, insulin pump consumables etc) are heavily subsidised, and continuous and flash glucose monitoring devices and consumables are free at the point of sale for all people with type 1 diabetes under the age of 21 years, all people with type 1 diabetes over the age of 21 years with a low income healthcare card, and
people planning for and during pregnancy. Registration to the NDSS is free for all people with diabetes in Australia. Diabetes Australia administers the NDSS on behalf of the Commonwealth Government. We are involved in ongoing advocacy to broaden access to diabetes technologies to a wider cohort of people living with diabetes.

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy

THE LOWDOWN – #HyposHappen is a social media campaign, focusing mainly on people living with type 1 diabetes and giving them a voice to discuss their stories. The diabetes community responded generously sharing their experiences of the mental and physical impact of hypos. The Lowdown was featured on all our social media channels and was supported via its own hashtag for people to share their stories, a Facebook Q&A, an online conversation and Facebook advertising. The campaign received an overwhelmingly positive feedback from our community and proved once again to be one of our most successful campaigns. https://thelowdown.org.au

The IF I HAD KNOWN campaign features real stories of people when they were first diagnosed with type 2 diabetes. The campaign encourages proactive and informed discussions between people with type 2 diabetes and their general practitioners at the point of diagnosis, and throughout their care, to drive early action on diabetes management. The development of the campaign was informed by focus group research that looked at the key challenges faced by people newly diagnosed with type 2 diabetes. https://ifihadknown.com.au

TAKE DIABETES 2 HEART is about inspiring people with diabetes, and the people who love them, to take positive steps to better heart health. We want people with diabetes, and the husbands and wives, sons and daughters, nieces and nephews who love them, to take diabetes to heart. If you have a loved one living with type 2 diabetes, we are encouraging you to have a heart-to-heart conversation about looking after their health. https://takediabetes2heart.com.au

4400 REASONS TO END AMPUTATIONS is about raising awareness of the need for urgent action to address diabetes-related amputations in Australia. Currently there are 4,400 amputations performed in Australian hospitals every year – and up to 85 per cent of these could be prevented. Diabetes Australia is leading the call for a Diabetes Amputation Prevention Initiative to help end amputations. https://www.diabetesaustralia.com.au/4400-reasons
The IT'S ABOUT TIME campaign focused on the need for earlier detection of type 1 and type 2 diabetes. https://www.itsabouttime.org.au

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation
Details of the Diabetes Australia Research Program, including funded research can be found here: https://www.diabetesaustralia.com.au/research-advocacy/diabetes-australia-research-program/

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?
Fortunately, medication and diabetes supplies were not interrupted by COVID-19. Depending on where people live in Australia, many people with diabetes found their regular diabetes healthcare appointments had pivoted to tele-health, however that was dependent if the city/town was in lockdown.

Participant Profile – Diabetes Canada

Website: https://www.diabetes.ca/

What is the mission of your organization?
To lead the fight against diabetes by 1) Helping those affected by diabetes to live healthy lives; 2) working to find a cure; 3) Preventing the onset and consequences of diabetes.

Describe the type of work your organization/ entity does in the field of diabetes:
Diabetes Canada is the registered national charitable organization that is making the invisible epidemic of diabetes visible and urgent. Diabetes Canada partners with Canadians to End Diabetes through:
• Resources for health care professionals on best practices to care for people with diabetes;
• Education for patients and their caregivers;
• Advocacy to governments, schools and workplaces; and
• Funding world-leading Canadian research to improve treatments and find a cure.

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
To share with members Diabetes Canada's Diabetes 360° nation-wide strategy framework that was developed by 120 diabetes stakeholders over more than a year of rigorous effort. Diabetes 360° contains evidence-based recommendations aimed at improving patient outcomes. It will enhance the prevention, screening and management of diabetes to achieve better health for
Canadians. Based on the successful 90-90-90 target adopted by UNAID, Diabetes 360° will reduce unnecessary health care spending by billions of dollars and improve the lives of millions of Canadians.

It would be our intent to share the Diabetes 360° strategy framework as an opportunity for others to consider adoption for their jurisdictions. We would be pleased to share our journey from the framework’s development to the federal government’s adoption, so others could benefit.

We also wish to learn from others about the diabetes frameworks that have been implemented internationally and of their outcomes to date.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.

Diabetes Canada advocates to provincial and territorial governments for public coverage of diabetes medications, including insulin, diabetes supplies and devices, including insulin pumps and continuous glucose monitoring devices. We advocate for patient choice of the therapy that best meets the unique needs and preferences of the individual living with diabetes.

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy

News of our advocacy success:
In 2021, the 100th anniversary year of the discovery of insulin, Diabetes Canada launched the national campaign, We Can’t Wait Another 100 Years to End Diabetes. On the occasion of this 100th anniversary, we are celebrating the Government of Canada’s confirmation of a nationwide diabetes strategy by both committing resources in our Federal Budget 2021 and in passing into law Bill C-237, An Act to Establish a National Diabetes Framework. As a result of the new law, the Minister of Health must engage a broad consultation process with provincial and territorial governments and other stakeholders and then present in Parliament by June 29, 2022 a diabetes framework for Canada based on our Diabetes 360° strategy framework.

Other initiatives:

The Canadian Diabetes Prevention Program (CDPP) - this 12-month wellness program provides:
• a personal health coach – you’ll have regular telephone sessions to discuss your learnings, set personal goals, and guide you in positive lifestyle changes
• online education modules, tools and resources
• health tracking to help you create small yet lasting changes
• monthly workshops to help you reach your goals
• Use infographics to share messages: Low literacy healthy plate infographic; Reduce sedentary time infographic
• EMR (electronic medical records) work in province of Newfoundland to address screening for diabetes (prevention) -> reminds physicians to screen for diabetes in appropriate patients
• A Diabetes Simplified program -> education program for primary care providers
• Effort is made to ensure that all of our resources are at a literacy level that is accessible
• Virtual Diabetes Education sessions improve health literacy (eating well with diabetes, active living with diabetes)
• Our communications campaigns (e.g., End Diabetes, diabetes awareness, awareness of complications, can’t wait another 100 years)
• Publish Clinical Practice Guidelines related to nutrition, physical activity, prevention
• Influence healthy public policy related to - restriction marketing to kids, healthy nutrition policy, taxing SSBs, active living
• Promote mental health in joint project with the Juvenile Diabetes Research Foundation
• Research funding to investigate etiology as well as potential ways to prevent type 2 diabetes
• Partner with organizations for wellness days (health promotion, prevention & screening)
• Partnering with the Public Health Agency of Canada and other partners on CANRISK, to encourage Canadians to assess their risk of developing type 2 diabetes
• Provide patient-facing webinars: Back to School with T1D; Influenza Vaccines; Travel; Transitions with T1D; Virtual Care & T2D; Liver Disease; Celiac Disease & T1D; Diabetes Distress; Sex, Drugs & Diabetes.
• Present an "Ask the Experts" video series: Physical Activity; Canadian Diabetes Prevention Program; Financial Assistance; Mental Wellness; Complications: gastroparesis; Transitioning from paediatric to adult care; Medication management; 100 Years of Insulin; Advocacy & Self-Advocacy; Diabetes & Driving; Celebrating with Diabetes.
• Present a “How 2 Type 1” video series: Insulin – how it works, Carbs – matching food & insulin, Exercise – balancing fuel, activity & insulin, Insulin doses – in 90 seconds or less, Why bother/are you ready?, Hypoglycemia – what it is and how to stop it, Common "mistakes" and how to fix them, Eating out, Staying motivated.
• Offer “Peer Connect” regional sessions: occur quarterly with a keynote guest expert to promote health literacy.
• Present a Diabetes Canada Podcast: 2 monthly episodes, recent topics including molecular changes, bone health, and sight loss.
• D-Camps virtual sessions: weekly youth-oriented sessions with opportunities for connection and key learning outcomes.
Please share any news, work, or events your organization is doing or plans to do regarding research and innovation

Diabetes Canada has funded some of Canada’s most renowned scientists and clinicians, and although their research is diverse in scope, the key goals of every diabetes researcher remain the same—to improve the quality of life of people living with diabetes or to find a cure. Over the more than 70 years it has been in operation, Diabetes Canada has funded over $140 million in research grants, awards and partnerships to scientists and clinicians across the country in their quest for new and innovative developments in the prevention, treatment, and management of diabetes.

Promising, innovative and impactful research is currently underway across Canada. From foundational science studying how beta cells receive signals to release insulin, to management of type 2 diabetes and obesity, to new coaching techniques for women with gestational diabetes, to the development of the artificial pancreas and new technologies for the treatment of type 1 diabetes, our funded researchers are committed to breakthrough research that will end diabetes. Diabetes Canada funds an annual investigator-driven, open research competition. The annual competition welcomes investigators from all research pillars and at any stage in their research career to apply. Diabetes Canada’s 2021 research funding competition will be awarding 15 End Diabetes:100 Awards. Each of the 15 awards commits a $100,000 operating grant annually for three years to support brilliant scientists and provide them with the freedom, autonomy, and resources to set them on the road to breakthrough discoveries.

The objective of the End Diabetes:100 Awards are:

- To support researchers in the discovery of the biomedical, clinical, health services, and/or population health factors that lead to the onset and progression of all types of diabetes and related complications.
- To develop solutions aimed at the prevention, management, and finding a cure(s) for people living with diabetes.

Over 140 applications were received for the 2021 competition. Applications were carefully reviewed by a multidisciplinary review panel consisting of scientific and clinical experts, along with persons affected by diabetes (including family/caregivers), to provide the perspective of people living with diabetes. Funding decisions will be made in December 2021.

Other Research Awards

Diabetes Canada also funds two annual peer-nominated researcher awards. The Early Career Researcher Award recognizes outstanding research conducted in Canada by young scientists in the field of diabetes. The Lifetime Achievement award is bestowed upon a prominent Canadian MD or PhD medical scientist who is recognized by their peers for longstanding contribution to the Canadian diabetes community and a leader in diabetes research. Each award consists of a personalized plaque, a cash award and a presentation ceremony.
Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?

Newly-released Canadian data indicate that, by April 2020, hospitals were seeing a 50% drop in ER visits (21). A decrease in emergencies, unfortunately, does not tell a complete story, as it cannot capture the impact of delayed care. During the early pandemic period—defined as March to June 2020—admissions for major cardiac events and other cardiac issues dropped by 20% and 21%, respectively, while 22% fewer people were admitted to ICU for cardiac conditions and strokes, compared to the same time period the previous year (22). Additionally, there was a 21% drop in urgent cardiac surgeries, such as bypass procedures and pacemaker insertions (22). Since diabetes contributes to 30% of strokes and 40% of heart attacks, it is reasonable to assume that a large proportion of patients who experienced delayed care were people with diabetes with complications (23).

Canadian data revealed a significant increase in the frequency of DKA at diagnosis and an increase in the incidence of severe DKA, even though the number of children presenting with newly diagnosed type 1 diabetes was similar to the same time period the previous year (41,42).

Summary results of a public survey conducted in May & June 2021 on how COVID-19 was affecting Canadians with diabetes are as follows:

Like for other Canadians, COVID-19 has been a stressor for respondents, many of whom report heightened concern about contracting the disease given the additional risk that is posed by living with diabetes and feelings of isolation or loneliness.

Most have not had struggles with accessing medications or health care.

A substantial minority have experienced added financial worries since the onset of COVID-19 that affect their ability to manage their diabetes. Respondents are quite split on level of concern for personal physical, mental and emotional health, and on experience of feelings of anxiety and isolation.

A third of respondents have had medical appointments canceled or deferred, but luckily that has not affected the health of most of them adversely, though it has been stressful for many.

About half of respondents have had virtual medical visits since the pandemic started, which they have overwhelmingly enjoyed. Most would prefer more virtual visits in future, continuing after the COVID-19 pandemic, and a majority support provincial and territorial shifts to virtual care.

Roughly three-quarters of respondents have received one of two doses of the COVID-19 vaccine, with roughly 10% fully vaccinated and a similar amount not yet vaccinated. Attitudes toward the vaccine were overwhelmingly positive and hopeful, with many respondents also expressing frustration with governments’ rollout, communication, and lack of prioritization for people living with diabetes; a small minority expressed outright distrust and refusal to receive the vaccination.

There were initial concerns about insulin supply (and other medications). There were concerns about supply chain, but also hording. There did not end up being a major issue but there were pockets of supply challenges within Canada.
What is the mission of your organization?
Our mission is to make every citizen of Malawi aware of the dangers diabetes poses to them.

Describe the type of work your organization/ entity does in the field of diabetes:
Diabetes is claiming a lot of lives in Malawi because of lack of awareness. DIABETES AWARENESS ASSOCIATION (DAA) was therefore created with the intention of helping in sensitization about diabetes across the country by carrying out awareness campaigns across the country and in addition to this creating an NCD prevention and health promotion programs or NCD surveillance, monitoring and evaluation on diabetes.

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
We believe Forums create a discussion environment by saving any information posted on a certain topic for others to see at any time, thus people can have high-quality discussions since they would have time to think about and research the topic/comment at hand. There is a freedom of speech, and people can write in any form they want (chatting style, diary style, etc.) Due to continuous participation (e.g. students) increase their writing skills and habits, making them more responsive and knowledgeable of others’ ideas. Relationships can easily be made between people through active comments. In a forum, people of different ages, points of view, backgrounds, and experience can share information on a certain topic which would conclusively offer a broad response to the topic at hand.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
One of our goals and objectives is to give easy access of insulin to all Malawians regardless of age, status or affiliation. In this view, we have already engaged stakeholders in order to fulfill this goal. Our aim is to source out insulin especially for those in the low-income areas and make it available to all.

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy.
It has been noted that a serious problem exists in the country where 4 out of 5 people die due to diabetes without knowing what really killed them even though information is available.
country also at the moment does not have any NCD prevention and health promotion programs or NCD surveillance, monitoring and evaluation on diabetes available. People do not have the understanding of exactly how deadly the disease is. According to the research conducted by the World Health Organisation, it has indicated that 94.4% of the infected Malawians can survive if provided with the information because only 6% of the infected take up the initiative to know what they are suffering from. The research also revealed that the levels of people suffering from diabetes are higher in rural areas as compared to urban areas. The results showed that 9.2% of the people in the rural areas are suffering from diabetes and 7.4% in the urban areas. This is attributed to the lack of awareness programs in the country.

According to the research it was also noted that there are three main risk factors which have triggered diabetes in the country. It shows that the country has a high level of alcohol consumption both in the urban and rural areas and is higher in men as compared to women. The other risk factor which has shot up the diabetes level is physical inactivity. It shows that Malawians are inactive when it comes to exercising which has also led to the other risk factor obesity. The country does not have any action plan on these risk factors to date.

Diabetes is claiming a lot of lives in Malawi because of lack of awareness. DIABETES AWARENESS ASSOCIATION (DAA) was created with the intention of helping in sensitization about diabetes across the country by carrying out awareness campaigns across the country and in addition to this creating an NCD prevention and health promotion programs or NCD surveillance, monitoring and evaluation on diabetes.

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation

We believe the most essential thing to do would be a nationwide survey as most data being used now is outdated. The survey will act as a measuring tool and a basis on which an NCD prevention and health promotion programs or NCD surveillance, monitoring and evaluation on diabetes will be made.

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?

Covid-19 pandemic has greatly hit our health system and this is major setback for a health system which on its own is already overburdened and under-funded.

To begin with, Recently the country was on a verge of collapse when India was on lock down for a period of time as 95 % of affordable metformine,Gribalamide and insulin come from India. Most patients especially in the rural areas are leaving below the poverty line and can not afford the Denk brand. Secondly there has been an increase in price as demand is high and supply is low and this has forced patients to dig deep into their pockets just to access the drugs. Many diabetes clinic have been forced to shut down and this had led to increase in the number of diabetes related deaths and complications.
What is the mission of your organization?
Facilitating the community to gain control over their lives by nurturing their innate capacities to make their own choices

Describe the type of work your organization/ entity does in the field of diabetes:
Activities:
1. Health education on Diabetes - prevention, treatment and care using communication aids.
2. Checking Body Mass Index, Blood pressure and Random blood sugar.
3. Identifying persons with diabetes, known diabetes and those in the pre-diabetic stage and systemically follow them for counseling, diet and nutrition guidance, physical exercises, appropriate referrals for further care, relaxation techniques for stress free life style.

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
Networking, getting updates and sharing

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
No information given.

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy

World Diabetes Day Observed
The World Diabetes Day was observed at EMPOWER Generic Medical Store, Beach Road on Thursday – 14.11.2019.

World diabetes day is observed on every November 14. The theme for the world diabetes day 2019 is family and diabetes. This theme highlights the importance of family in management, prevention, care and creating awareness about diabetes. This day tries to create awareness about the importance of taking the necessary steps to control diabetes. Diabetes is affecting a huge population today and there is an urgent need to take prevention steps at the right time. Right precautions can help you prevent yourself and your family from the risk of diabetes. If left uncontrolled diabetes can lead to many severe complications that can affect any other organs.

A Diabetes Screening Camp and exhibition was organised by EMPOWER Diabetes Health Centre.
in association with Thoothukudi District Diabetes Association on the premises of EMPOWER Generic Medical Store. Advisor of Thoothukudi District Diabetes Association Dr.R.ArulPrakash inaugurated the programme and spoke about the ill effects of Diabetes and necessary steps to prevent diabetes. Founder of Indian Diabetic Community and Director of the EMPOWER Diabetes Health Centre A.Sankar said that, Over the past decade, diabetes prevalence has risen faster in low and middle-income countries than in high-income countries. Diabetes is a major cause of blindness, kidney failure, heart attack, stroke and lower limb amputation. Healthy diet, physical activity and avoiding tobacco use can prevent or delay type 2 diabetes. In addition diabetes can be treated and its consequences avoided or delayed with medication, regular screening and treatment for complications. A team of Medical Personals screened many general public. The blood sugar level, Blood Pressure and Body Mass Index where tested. Besides, symptoms causing diabetes, need for consuming healthy and nutritious diet, maintaining diet control, diet chart methods to prevent diabetes and to lead a healthy life style with physical exercise where displayed in charts. EMPOWER Manager R.Lalithambigai proposed vote of thanks.

**Please share any news, work, or events your organization is doing or plans to do regarding research and innovation**

No information given.

**Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?**

The referral network was built with trained doctors, nurses and peer educators which was spread over various parts of Thoothukudi block. This network has contributed to the sustainability of the project. The trained peer educators motivate those with pre –diabetics and diabetics to adopt and healthy life style practices such as drug compliance, right diet and physical exercises. The private doctors trained had become more confident of providing the comprehensive care to treat diabetics. The IEC materials produced by the project are used by the doctors to educate the patients. In workplaces where there are medical centers ie outpatients clinics for the workers, diabetes and hypertension screening and treatment have been integrated and prioritised. The salt workers have started to receive subsidised diabetic care at the medical centers. Besides the medical centres for fisher folks also receive good diabetic care by trained doctor. There were programs on self care training for the diabetes patients imparted which would go in a long way to help themselves.

The Thoothukudi District Diabetes Association was launched for the sustainability of the
project. After the project period the activities of the project would be sustained with support of the stakeholders. Even after the project period there were requests from the stakeholders to conduct screening camps which were conducted by EMPOWER and Thoothukudi District Diabetes Association.

Besides, EMPOWER has initiated a low cost drug store called Janaaushadhi in a prime location of Tuticorin. This Janashudhi is good outlet to attract the diabetic patients who were in follow up. Now they come to this outlet to buy drugs and also to test random blood sugar, check their BMI and BP. They are guided to comply visit their doctors for regular.

**Participant Profile – European Diabetes Forum**

**Website:** [https://www.eudf.org/](https://www.eudf.org/)

**What is the mission of your organization?**
EUUF wants to ensure the translation of research into policy actions towards better diabetes care at national level

**Describe the type of work your organization/ entity does in the field of diabetes:**
The mission of EUDF is to ensure that policy action can be directed towards driving better diabetes care at national and European level. The non-profit purposes of international utility of the Association shall be, within the European Union and worldwide to: (a) Provide an international powerful and cohesive platform in which diverse stakeholders are working together to further the improvement of diabetes prevention and diabetes care; (b) Enable healthcare systems to cope with the diabetes pandemic while achieving the best possible outcomes for people with diabetes; (c) Ensure the translation of research into policy actions towards better diabetes care at national and international level; and (d) Defend, represent, and promote in the broadest sense of the word the common interests of its Members. To that effect, the Association may develop, alone or in collaboration with third parties, directly or indirectly, all activities related, directly or indirectly, to its purposes including, but not limited to: (a) Facilitating and supporting the cooperation between Members and/or stakeholders to address and work on matters related to diabetes care by: a. Exchanging, collecting and distributing information on diabetes, diabetes prevention and diabetes care; b. Addressing diabetes issues through the development of policy actions at national and international level; c. Developing and coordinating joint projects of Members on diabetes care; and d. Communicating on the activities and achievements of the Association; (b) Disseminate information and issue publications; (c) Organise and arrange congresses, seminars, workshops,
and other programmes and convenings at international and national levels; (d) Collect and analyse statistical data; (e) Participate in European Union or other public authorities’ programmes, calls for proposals of the European Union, national governments or other public and semi-public authorities, and in general to apply for grants from the European Union, national governments or other public and semi-public authorities; and (f) Cooperate with and assist other initiatives and/or organisations having a purpose similar to the purposes of the Association, as well as other regional and/or international initiatives and/or organisations.

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
To support the implementation of the GDC workstreams in Europe and to contribute to discussions and ways to implement the objectives and plans. Overall the key objectives of the GDC are aligned with the ‘raison d’être’ of eUDF which is improving the lives of people with diabetes. EUDF is applying to the GDC forum membership to ensure a close collaboration at the regional European level and to focus on Global/European priorities to better address diabetes challenges across the world and Europe and to better support/contribute to WHO GDC initiatives.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
In the EUDF Strategic Forum Self-care, Technology & Digitalization Continuously the objectives are to improve and innovate diabetes care, driven by policy action. - Open the dialogue on diabetes technology between the people with diabetes, manufacturers and regulators - Optimise the use of technology, digital health and innovative treatments to support self-care by people with diabetes, to prevent complications and support quality of life - Foster the introduction of innovative approaches and broader evidence for diabetes care into policy, and policy into action - Guide the relevant funding agencies on the focus and priorities for research - Prepare recommendations for the optimal use of technology & digital health to support self-care and provide guidance for regional/national translation

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy
The 3 existing Strategic Forums have in common the observations and plans that more health literacy is needed on the 3 priorities of EUDF: 1. Data and Registries - more education is needed towards people with diabetes and clinicians on the importance to collect and use data properly. 2. Integrated Care: more education is needed at local level to illustrate the benefits of integrated care and the continuity of diabetes care 3. Digitalisation, Self-Care, Technology: specific needs to increase digital literacy, both towards people with diabetes and probably even more important to clinicians.
Please share any news, work, or events your organization is doing or plans to do regarding research and innovation

In general the members of the European Diabetes Forum call for action to keep diabetes research high on the policy agenda. Several members have Diabetes Research as their core business as they are diabetes research foundations or supporting and conducting research in their respective domains.

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?
No information given.

Participant Profile – FIND: Foundation for Innovative New Diagnostics

Website: www.finddx.org

What is the mission of your organization?
FIND, the global alliance for diagnostics, seeks to ensure equitable access to reliable diagnosis around the world. We connect countries and communities, funders, decisionmakers, healthcare providers and developers to spur diagnostic innovation and make testing an integral part of sustainable, resilient health systems. We are working to save 1 million lives through accessible, quality diagnosis, and save US$1 billion in healthcare costs to patients and health systems. We are co-convener of the Access to COVID-19 Tools (ACT) Accelerator diagnostics pillar, and a WHO Collaborating Centre for Laboratory Strengthening and Diagnostic Technology Evaluation. For more information, please visit www.finddx.org

Describe the type of work your organization/entity does in the field of diabetes:
FIND is active in market access, technology development and evidence generation on integrated care delivery in the field of diabetes. Our market access activities include preferential pricing agreements with manufacturers of diabetes diagnostics, as well as trade and supply innovation projects. Technology development focuses on new technologies for self-monitoring of glucose and their suitability for use in LMICs through definition of a target product profile and performance/usability evaluations. Care delivery projects are planned to address evidence gaps in LMICs for implementation of NCD screening and care within infectious diseases programs.
What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?

We hope to contribute our know how and experience in the field of diagnostics to strengthen the provision of screening and (self-)monitoring tools and services for diabetes with the view to support the WHO goal of 80% availability of affordable basic NCD technologies. Interactions with the WHO GDC Forum members will be critical to our work to ensure that we take into consideration all relevant aspects of diabetes care to achieve sustainable and most impactful results.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.

Affordable pricing news & project (1 & 2) and ongoing project for glucose testing technologies (3)

1. https://www.finddx.org/newsroom/pr-18aug21/

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy

We are planning a CME module for pharmacist professionals in Cambodia and Vietnam on the value of self-monitoring as a recent survey we conducted showed very limited knowledge of pharmacy professionals around self-monitoring and this is a missed opportunity to provide education to people living with diabetes in the pharmacy when they collect any diabetes-related medication/supplies.

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation

Research on performance of new self-monitoring health technologies as per this RFP:

Qualitative research with people living with diabetes on their use of health technologies is planned in four LMICs (4 LMICs). Research on performance of point-of-care cardiometabolic devices is ongoing in Nepal. Research on NCD screening integration into COVID-19 rapid antigen screening is ongoing in South Africa.
Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?
Access to diagnostics and monitoring tests/tools was impacted by COVID as people with diabetes were less able to go out and either receive a test at a healthcare facility or obtain supplies in pharmacies. Resources in countries allocated to procurement of self-monitoring supplies were diverted to COVID (first tender in a LATAM country to procure meters/strips specifically for self-monitoring was delayed/cancelled as resources were re-allocated to COVID).

Participant Profile – Grand Challenges Canada

Website: https://www.grandchallenges.ca/

What is the mission of your organization?
To catalyze innovation that saves and improves the lives of the most vulnerable in Canada and low- and middle-income countries.

Describe the type of work your organization/ entity does in the field of diabetes:
Grand Challenges Canada supports innovators in low-and-middle income countries that are focused on saving and improving lives. There is no specific program focused on diabetes, but the organization puts out RFPs for innovators who may have innovative projects that can support the health and improve life quality of those living with diabetes.

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
Grand Challenges Canada hopes to expand its network and understanding of the issues surrounding diabetes in a global health perspective.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
No information given

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy.
No information given

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation.
No information given.
Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?

No Information given

**Participant Profile – Health Finance Institute**

Website: [https://www.healthfinanceinstitute.org/](https://www.healthfinanceinstitute.org/)

**What is the mission of your organization?**

The Health Finance Institute (HFI) advocates for and forges data-driven/evidence-based innovative financing partnerships to take on the finance deficit of the deadliest non-communicable diseases worldwide.

**Describe the type of work your organization/ entity does in the field of diabetes:**

The Health Finance Institute (HFI) advocates for and forges data-driven/evidence-based innovative financing partnerships to take on the finance deficit of the deadliest non-communicable diseases (NCDs) worldwide. HFI’s health economics and innovative finance programs work together to articulate the investment case for NCDs and facilitate public-private partnerships to close the financing gap.

Regarding diabetes specifically, HFI has designed a fully implementable type 2 diabetes model, as well as early modeling for type 1 diabetes. HFI’s type 2 diabetes model explores the impacts of increasing access to, and equity of, diabetes screening and treatment in different populations. This model can be used to forecast the health and economic impacts of potential type 2 diabetes interventions or policies and help the public and private sector, including health insurance funds, make the economic and business case for investing in type 2 diabetes.

Equipped with health, economic, and financial expertise, HFI is currently in the process of launching two diabetes programs: one in Mexico and one in Armenia. HFI will work with local partners in Mexico to increase access to high-quality end-to-end solutions for quality diabetes management, especially to fill gaps such as access to life-saving medical devices for youth living with type 1 diabetes. This pilot will form the foundation of the global Devices for Development Consortium that will initially focus on building real-world data and evidence on continuous glucose monitors for children and youth in under-resourced settings to improve the quality and cost-effectiveness of diabetes care. Additionally, HFI will partner with the Danish Red Cross to create the first social impact bond for type 2 diabetes in Armenia.
What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?

At the Health Finance Institute (HFI), we believe that nobody chooses disease. Our mission to democratize impact investing for non-communicable diseases (NCDs) motivates us to join this forum to lend our health, economic, and financial expertise and contribute to the vision of the Global Diabetes Compact: "a world where the risk of diabetes is reduced and where all people who are diagnosed with diabetes have access to equitable, comprehensive, affordable and quality treatment and care." As a member of various advocacy groups such as the NCD Alliance, HFI is prepared to fulfill the forum’s objectives to "Undertake advocacy efforts for galvanizing support for, and raise awareness of, the Vision and Goals of the WHO Global Diabetes Compact" and "Promote networking for knowledge sharing." More broadly, HFI recognizes that this forum is an important step in achieving the Sustainable Development Goals (SDGs) by 2030, including SDG 3 and SDG 17.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.

Supported by the leadership of the International Finance Facility for Immunization (IFFIM), GAVI, Citi, Crédit Agricole, and Innovative Humanitarian Financing Forum (IHFF), and in partnership with the Life for a Child (LFAC) initiative, the Health Finance Institute (HFI) is spearheading the Devices for Development Consortium (D4DC). D4DC is aimed at addressing the market failures around quality glucose measurement in under-resourced settings. Via the means of an Advance Market Commitment (AMC), D4DC endeavors to bring about significant price drops in the device market, thereby also shepherding a market opening for diabetes. HFI’s first D4DC pilot program will take place in Jalisco, Mexico, with the potential for a national scale-up.

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy

The Health Finance Institute (HFI) has recently (Oct 12, 2021) hosted a roundtable, in partnership with the NCD Alliance, discussing the importance of financing the NCD response, including the Best Buys, as part of the Building Back Better Agenda. Further, HFI continues to publish peer-reviewed and gray literature articles on the science of prevention and early access to diagnosis and care. A full list of published articles, and past and future events are available on HFI’s website.

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation

The Health Finance Institute (HFI) serves as a thought and research leader for non-communicable diseases (NCDs), health economics, and innovative finance. We hold innovative finance training sessions, organize virtual and in-person events, and facilitate multi-stakeholder decision-making. Some of our recent events include a UN General Assembly 76 side event on blockchain and
philanthropy and a high-level roundtable in partnership with the NCD Alliance on integrating NCDs in COVID-19 recovery agendas. In addition to events, HFI is frequently invited to contribute to prominent health and science publications including PLOS and Foresight Global Health.

Further, HFI has developed an econometric model to analyze and forecast the impact of various type 2 and type 1 diabetes scenarios in specific implementation and country settings. This particular application can be used for partnerships as they may arise due to the activities of the Global Diabetes Compact Forum.

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care? COVID-19 has undoubtedly impacted our partners and stakeholders, not least because diabetes was a key driver of increased morbidity in the COVID-19 pandemic. HFI has drawn attention to this issue in several articles, including “We Need Better NCD Data for COVID-19 Response in LMICs” via ICTworks and “COVID-19 and NCDs: A Deadly Combination” via HFI’s Medium page.

Participant Profile – International Alliance for Diabetes Action (IADA)

Website: [http://www.iadadiabetes.org/](http://www.iadadiabetes.org/)

What is the mission of your organization? IADA exists to ensure vulnerable people in humanitarian crises have access to quality diabetes care; and to stop the unnecessary disability and death of people living with diabetes in these settings.

Describe the type of work your organization/ entity does in the field of diabetes: IADA is a partnership of over 40 international organizations with an interest in diabetes from different sectors that is developing concrete collaborative initiatives that will increase access to and quality of care for people with diabetes in humanitarian settings. The partnership leverages the unique skills, expertise, and capacities of both public and private member organizations, to develop and implement bold initiatives with policy-relevant outcomes to make certain that quality diabetes care is globally accessible to the most vulnerable populations affected by humanitarian crises. IADA’s four key thematic areas are [1] Clinical and Operational Implementation, [2] Access to Essential Medicines and Diagnostics, [3] Policy, Financing and Advocacy, and [4] Data and Research. IADA’s activities include providing expertise around diabetes care in humanitarian settings leveraging the broad knowledge and experience of the consortium members; help build
consensus on critical issues; agenda setting by identifying key gaps and bringing awareness to critical issues that need to be prioritized and addressed; provide a platform for organizations to connect and collaborate; convene meetings such as symposia, webinars and workshops; facilitate collaboration and synchronization of current and planned activities between organizations; develop open-access training materials and educational resources; participate in advocacy to elevate the voices of people living with diabetes in humanitarian settings, push the international agenda and create accountability; and with the operational depth of consortium members provide technical and implementation support for diabetes care in humanitarian settings

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?

The WHO Global Diabetes Compact and the recent landmark Resolution “Reducing the Burden of Noncommunicable Diseases through Strengthening Prevention and Control of Diabetes” (WHA74.4) that was adopted at the World Health Assembly in May 2021 both include people with diabetes who are affected by humanitarian crises, to ensure uninterrupted treatment for people living with diabetes in humanitarian emergencies. Members of IADA have participated in the WHO Stakeholder meetings over the past year to contribute to the development of the Global Diabetes Compact. We are excited about the work that the WHO has planned and would like to support and contribute to this important initiative. As such, IADA can provide expertise around diabetes care in humanitarian settings leveraging the broad knowledge and experience of the consortium members; we can help facilitate collaboration and synchronization of current and planned activities between organizations; we can contribute to the development of training materials and educational resources; participate in advocacy to elevate the voices of people living with diabetes in humanitarian settings; create accountability; and with the operational depth of consortium members provide technical and implementation support for diabetes care in humanitarian settings. There is much overlap and complementary work that is planned between the Global Diabetes Compact and IADA. Therefore, by joining the Global Diabetes Compact Forum we hope to ensure good communication, facilitate collaboration, provide support and ultimately do the best we can to improve the delivery of diabetes care for people living in low- and middle-income countries and affected by crises.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.

IADA has a working stream dedicated to improving access to medicines and diagnostics in humanitarian settings (co-led by Helen Bygrave with the MSF Access Campaign and Jing Luo with the University of Pittsburgh) with various activities underway and planned. A few activities are listed here: Currently, consortium members are developing insulin treatment algorithms for type 1 diabetes in low-resource settings for the WHO. Consortium members have contributed to research, conversations, and stakeholder meetings on insulin thermostability with various
organizations, including the WHO, to help identify the key challenges and possible solutions. We have been involved in work around bundling of insulin and supplies in humanitarian settings and have been collaborating with the Clinton Health Access Initiative to inform and support their work on costing the bundle for insulin-requiring patients in LMICs. We plan on collaborating with the WHO to ensure awareness amongst humanitarian agencies of the WHO NCD kit, supporting agencies to develop their own list where required. Moreover, our plans are to document WHO NCD kit deployment to inform its periodic revisions and better identify needs and challenges for its appropriate use and improve diabetes care readiness. We plan on working with PATH, CHAI, FIND and other to define and pilot a simple and cost-effective bundle of diabetes medications and supplies for humanitarian settings and evaluate the feasibility, cost effectiveness and acceptability of continuous glucose monitoring in humanitarian settings. Moreover, we hope to coordinate an action plan to support the implementation of the WHO Resolution on NCD/Diabetes Care.

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy

Within our working stream of clinical are and operational guidance (co-led by Philippa Boulle (MSF) and Sylvia Kehlenbrink (BWH)), we have been developing clinical guidelines on the use of insulin in individuals with type 1 diabetes in humanitarian settings, as noted above. We have also established Diabetes Education for All (DEFA), led by Nuha El Sayed (Harvard Medical School/American Diabetes Association). DEFA was established to provide comprehensive open access diabetes education and clinical guidance for healthcare providers and create a portal for support and educational material for individuals living with diabetes in humanitarian settings. The goal of DEFA is to create a global online collaboration network to empower communities of healthcare professionals and people living with diabetes in humanitarian settings to collaborate and communicate internationally (DEFAdiabetescommunity.org). Through this online education portal with applications in mobile health and several languages, health care providers and trainees will be able to access at no cost academically rigorous content and resources, such as on-demand educational modules, expert opinion, medical guidelines and protocols, clinical case discussions, educational materials, clinical and operational toolkits and clinical demonstrations. It will also provide education and a psychosocial support platform for individuals living with diabetes and their families. We have also established a working group on nutrition in humanitarian settings with various organizations including the World Food Programme, MSF, UNHCR, ICRC, UNRWA, WHO and the IRC, to exchange ideas, identify needs, and collaborate on improving nutrition in humanitarian settings both to prevent and manage diabetes. We are planning an interagency food environment survey across humanitarian settings.
Please share any news, work, or events your organization is doing or plans to do regarding research and innovation

The goal of our working stream on Data and Research is to strengthen monitoring and evaluation of diabetes programs in humanitarian settings. As such we completed an interagency study (UNITED study) looking at diabetes care across four humanitarian organizations (ICRC, IRC, MSF, UNHCR) and hope to submit the manuscript for publication shortly. Consortium members (University of Pittsburgh, Brigham and Women’s Hospital, Life for a Child, CHAI, and LSHTM), have also submitted a grant application to complete a clinical trial looking long-acting analogue insulin use in individuals with type 1 diabetes in terms of safety, efficacy, quality of life and cost, compared to human insulin, in a low resource setting. Consortium members and the Informal Interagency Working Group on NCDs in Humanitarian Settings (led by UNHCR) have been collaborating to develop a set of diabetes-related indicators. We plan to develop a prototype surveillance system, implement, and evaluate it in at least one setting. We are working on a research prioritization surgery to identify the key research needs for diabetes care in humanitarian settings and facilitate and track research collaborations among alliance members. It is our goal to improve processes for dissemination of findings, publications, and best practices about diabetes care and prevention in humanitarian crises to all audiences and host annual symposia and webinars. Thus far we have hosted two symposia, in April 2019 and December 2020. The third symposium is planned for April 2022

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?

Yes, our stakeholders have been affected by the COVID-19 pandemic in various ways, depending on their area of work. This has been most pronounced with the implementing humanitarian organizations who have seen supply chain disruptions for insulin, other diabetes medications and diagnostic supplies and access challenges for people living with diabetes. For example, our colleagues working at the Université Catholique de Bukavu, Democratic Republic of the Congo, reported reduced access to diabetes medicines and glucometers, as well as unavailability of reagents for laboratory testing (such as A1c) and increased drug prices for insulin, oral agents and glucose test strips in the wake of COVID-19. Moreover, they described challenges for people living with diabetes accessing the health centers, therefore relying on traditional medicines. Advocates with T1 International and the Sonia Nabeta Foundation, as well as UNHCR and UNRWA described similar access challenges for people living with diabetes during the pandemic.
What is the mission of your organization?
Our vision is to see patients at the centre of healthcare throughout the world. Our mission is to help build patient-centred healthcare worldwide.

Describe the type of work your organization/ entity does in the field of diabetes:
As an entity in official relationship with WHO, we empower patients, undertake research and advocate the shaping laws and policies to improve global health and the establishment of patent centred quality, safe, accessible, acceptable and affordable healthcare.

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
Have the opportunity shape the diabetes healthcare ecosystem and empower patients, undertake research and advocate the shaping laws and policies to improve global health and the establishment of patent centred quality, safe, accessible, acceptable and affordable diabetes healthcare.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
We are raising health literacy, providing tool kits, and running capacity building courses to make biosimilars, especially biosimilar insulins, accessible to all. Our Global Patients Congress during the World Health Assembly 2022 will be a keynote event for us.

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy
We are raising health literacy, providing tool kits, and running capacity building courses toon Precision Medicines (Precision Diabetes) and Gene Therapy (for some type 1 diabetics). Our Global Patients Congress during the World Health Assembly 2022 will be a keynote event for us.

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation
Our surveys on biosimilar and gene therapies will guide our policy.

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?
IAPO has for over 21 years prioritised NCDs. Our membership and board members are represented by type 1 diabetes patients. At the WHA we have over the past five years made
interventions in support of the establishment of patent centred quality, safe, accessible, acceptable, and affordable diabetes healthcare.

In 2020 we actively began to map patient journeys in NCDs in LMIC. A Methodology for Mapping the Patient Journey for Noncommunicable Diseases in Low- and Middle-Income Countries. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7853412/

Our Biosimilar Tool Kit has had over 1000 expert patients access it and shape their access to insulin advocacy. https://www.iapo.org.uk/sites/default/files/files/Part%201%20(1).pdf. The tool kit comes with practical advocacy skills https://www.iapo.org.uk/sites/default/files/files/Part%202%20(1).pdf

Our Global Patients Congress in 2020 was opened by a Type 1 Diabetes Patient who is a doctor together with the WHO’s Chief Scientist Dr. Soumya Swaminathan. https://www.iapo.org.uk/sites/default/files/files/GPC%202020%20Report%20(13).pdf

**Participant Profile – International Diabetes Federation**

**Website:** https://www.idf.org

**What is the mission of your organization?**
Promoting diabetes care, prevention and a cure worldwide.

**Describe the type of work your organization/ entity does in the field of diabetes:**
The International Diabetes Federation (IDF) is an umbrella organization of over 240 national diabetes associations in 168 countries and territories. It represents the interests of the growing number of people with diabetes and those at risk. The Federation has been leading the global diabetes community since 1950. IDF’s mission is to promote diabetes care, prevention and a cure worldwide. IDF is engaged in action to tackle diabetes from the local to the global level — from programmes at community level to worldwide awareness and advocacy initiatives.

The International Diabetes Federation is divided into seven regions, with the aim of strengthening the work of national diabetes associations and enhancing the collaboration between them.

The Federation’s activities aim to influence policy, increase public awareness and encourage health improvement, promote the exchange of high-quality information about diabetes and
provide education for people with diabetes and their healthcare providers.

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
Improve knowledge sharing and collaboration with other organisations working in the diabetes space.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
No information given.

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy
No information given.

**Participant Profile – International Diabetes Federation – Europe Region**

**Website:** [www.idf-europe.org](http://www.idf-europe.org)

**What is the mission of your organization?**
IDF mission is to unite the voice of people with diabetes and to engage all stakeholders in creating a person-centered diabetes ecosystem. Its vision is to improve the lives of people with diabetes.

**Describe the type of work your organization/ entity does in the field of diabetes:**
IDF Europe is the European chapter of the International Diabetes Federation (IDF). It is a non-profit, non-governmental organisation, established under Belgian law. IDF Europe is an umbrella organisation representing 70 national diabetes associations in 44 countries across Europe. We are a diverse and inclusive multicultural network, representing both people living with diabetes and healthcare professionals.

Our vision is to improve the lives of people with diabetes and our mission, in Europe, is to unite the voice of people with diabetes and to engage all stakeholders in creating a person-centred diabetes ecosystem.

Our priority objectives are:
- Improving access to care and quality of life for people with diabetes
• Increasing the voice of people with diabetes on all levels (#nothingAboutUsWithoutUs)
• Reducing diabetes incidence and preventing complications.

Through our activities, we aim to increase awareness, promote the exchange of best practices and quality information about diabetes, and to influence policy. Of key importance is promoting the understanding that diabetes is a serious condition and that people with diabetes can only live a long and healthy life through their own self-management and adequate support. It is also critical to understand that the diabetes curve can only be flattened by the creation of health-enabling environments addressing the determinants of health, and by the promotion of early action by healthcare systems including a shift in focus from treatment to prevention.

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?

Through our participation in the WHO Global Diabetes Compact Forum, we hope to join forces to promote urgent action on diabetes, with two main areas of focus: 1. Lowering the risks for people of developing diabetes and/or diabetes-related complication; 2. Ensuring access to equitable, comprehensive, affordable and quality treatment and care across Europe. We will support WHO Europe’s and other diabetes stakeholders’ advocacy work, at the national level, working in close collaboration with our Member Associations (https://idf.org/our-network/regionsmembers/europe/members.html) and at the EU level through our role as Secretariat of the MEP Interest Group on Diabetes (https://www.mepinterestgroupdiabetes.eu/) and our partnerships with other European diabetes and health related organisations.

IDF Europe also wishes to leverage its strong presence in Central and Eastern European countries to support implementation of the WHO Global Diabetes Compact initiatives in a region too often under-represented and where access issues are still very much present.

Being the European Chapter of the International Diabetes Association, our participation in the WHO Global Diabetes Compact Forum could support increased collaboration between regions when relevant and/or adaptation of global initiatives to the European context of global initiatives, when needed.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.

• Participation in the EU HTA stakeholder group
• Participation in the EUDF strategic forum on digitalisation and in the development of policy recommendation
• Participation in a stakeholder advisory group of the HTx Horizon 2020 project, aiming to create a framework for the Next Generation Health Technology Assessment (HTA) to support patient-centered, societally oriented, real-time decision-making on access to and
• reimbursement for health technologies throughout Europe.
• Events for World Diabetes Day on access to diabetes care:
  • 16 November 2021: How are digital technologies and AI improving access to diabetes care? Webinar hosted by Members of the European Parliament
  • 18 November 2021: Innovative financing for sustainable access to diabetes care in Central and Eastern Europe. How far are we from Universal Health Coverage?
• Development of a publication on innovation in diabetes care delivery, examining the use of digital technologies and AI for improved diabetes management and access to care.
• Development of country fact sheets (for each one of the countries of our Member Associations) on access to diabetes care, including access to insulin, diabetes technologies and digital health, accompanied by video testimonials of people living with diabetes and associations’ representatives
• Promotion of the need for better access to (newer) medicines and technologies through our social media and other communication channels, linked to the above activities as well as responses to EU consultations, e.g., Revised Pharmaceutical Legislation, HTA regulation, European Health Data Space

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy
• Collection and sharing of best practices from our Member Associations
• Development of lay guidelines on best practice diabetes management
• Development of a publication on innovation in diabetes care delivery, examining the use of digital technologies and AI for improved diabetes prevention.
• Centenary of insulin campaign: social media campaign, with two key objectives – raising awareness of the condition and addressing preconceptions/misconceptions about diabetes
• Participation in Horizon 2020 projects - Representing the voice of people living with diabetes in an EU-funded project and communicating project deliverables and outcomes. Building on the Feel4Diabetes Study, Digicare4Youfocuses on improving the prevention and management of Type 2 Diabetes in the community, using schools as an entry point. As well as setting up screening programmes in the community, the project will also look at engaging the community in building healthy lifestyles, and will develop an mhealth application to support better diabetes management

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation
• Development of a series of papers on innovation in diabetes (innovation in diabetes care delivery, innovation in diabetes technology, innovation in diabetes pharmacology)
• Participation in Horizon 2020 projects. ISLET is developing an advanced cell therapy for people living with Type 2 Diabetes, while Recognised is looking at determining the usefulness
• of the retina as a tool for identifying people with type 2 diabetes and cognitive impairment
• Participation in an IMI Project, Trials@Home, looking at the feasibility of moving clinical trials from the traditional clinic setting to the participant's immediate surroundings. These so-called Decentralised Clinical Trials make use of new, digital, innovations to improve clinical trial recruitment and retention, for example, for hard-to-reach and under-represented population groups, lower burden of the trial on participants, and improve research outcomes.

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?
Please refer to the report of IDF Europe’s Diabetes & COVID-19 survey which was conducted between August and October of 2020. The aim of the survey was to gather the perspectives from people with diabetes on their lives during the pandemic. The survey recorded responses from 3,480 people living with diabetes in 32 European countries.


Individual country profiles have been published for:
- Belgium
- Finland
- France
- Germany
- Ireland
- Italy
- Slovenia
- Spain
- Sweden

These are also available at https://idf.org/our-network/regions-members/europe/covid-19.html

Additional country reports to be released shortly:
- Greece
- Kazakhstan
- North Macedonia
- Portugal
- Romania
What is the mission of your organization?
Promoting diabetes care, prevention and a cure worldwide.

Describe the type of work your organization/entity does in the field of diabetes:
Our organization promotes the care and prevention of diabetes. We promote education through guidelines, webinars, and an annual congress. Advocacy is one of the main activities of our Associations. We provide healthcare for people in the entire South America and Central America Region. We are still fighting to get free access to insulin in some of our countries.

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
To raise the voices of diabetes.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
Our organization works hard through its associations, providing access to insulin and we work with the different levels of government in each country in the region to achieve access to insulin in all countries in the region. About health technology, we are organizing a specialized technology course in Diabetes with a total of 60 hours and up to 50 students.

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy.
We work intensively on prevention and health promotion and we have a program with the Argentine Diabetes Federation dedicated to the literacy of adults with diabetes.
Please share any news, work, or events your organization is doing or plans to do regarding research and innovation.
Our institution has an innovative program for diabetes educators through training guides, where the same language is spoken for associations that belong to our institution, such as the Argentine Diabetes Society (SAD), the Brazilian Diabetes Society (SBD), Paraguayan Diabetology Society (SPD), carry out research projects in basic sciences.

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?
COVID-19 had a great impact in our region. Routine health services were disrupted and large
amount of people living with chronic diseases, such as diabetes became seriously ill and died because they were infected with COVID-19.

The main reasons for the interruption of non-communicable disease care services were the cancellation of care, the decrease in available public transportation, fear of attending care centers, among others. On the other hand, detection programs for breast and cervical cancers were suspended. There are countries in our region where people with diabetes do not have free access to oral medications, insulin, supplies, and not even health care. In countries where these services are legally available, they have been interrupted or postponed because COVID-19 and its impact became the priority.
What is the mission of your organization?
IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.

Describe the type of work your organization/ entity does in the field of diabetes:
IFPMA is working with its member companies, WHO, and other key stakeholders to co-create innovative, multi-stakeholder solutions that will provide integrated diabetes diagnosis, prevention, treatment, and control of diabetes. Our industry is ready to work with national governments and other appropriate local stakeholders in LMICs to collectively work towards practical solutions that would sustainably improve the lives of PLWDs.

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
IFPMA and its members hope to participate in a real co-creation process to design practical and multistakeholder solutions that address the key barriers to access to diabetes products and care in LMICs.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
No information given.

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy
No information given.

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation
No information given.
Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care? No information given.

**Participant Profile – International Generic and Biosimilar Medicines Association (IGBA)**

**Website:** [https://www.igbamedicines.org/](https://www.igbamedicines.org/)

**What is the mission of your organization?**

The International Generic and Biosimilar medicines Association (IGBA) strengthens cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. Adopting a patient centric approach, IGBA is at the forefront of globally improving patients’ access to quality-assured, safe and cost-effective medicines by preserving competition as well as enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders; For more details, regarding IGBA and its member associations, see the IGBA website at: [www.igbamedicines.org](http://www.igbamedicines.org)

Our vision is to globally promote access to quality-assured, safe and cost-effective generic and biosimilar medicines, while enabling sustainable economic contributions for all stakeholders.

**Describe the type of work your organization/ entity does in the field of diabetes:**

Our raison d’être is affordable access to medicines, including for NCDs. All our activities are access driven.

**What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?**

Raise awareness regarding the challenges and opportunities for access to biosimilar insulins and analogs.

**Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.**

- IGBA-Medicines for Europe annual conference (with participation of WHO) : Goal 2030: Access for All (Sept 2021) [https://www.medicinesforeurope.com/events/annual21/](https://www.medicinesforeurope.com/events/annual21/)
- IGBA webinar (with WHO participation): Advancing Access for NCDs (2nd Nov 2021)
• 2nd Global Biosimilars Week (social media campaign) 1-5 November 2021

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy
IGBA does not have plans to have activities related to prevention, health promotion and health literacy since this is out of scope of our organization

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation
No information given

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?
No information given
What is the mission of your organization?
The International Rescue Committee helps people whose lives and livelihoods are shattered by conflict and disaster to survive, recover and regain control of their future.

Describe the type of work your organization/entity does in the field of diabetes:
The IRC aims to address NCDs at the onset of a crisis and throughout the recovery period. We work to identify patients who have already been diagnosed with NCDs and ensure they receive uninterrupted treatment and avoid developing complications; help people prevent NCDs; and strengthen health systems to address this growing burden of disease. The IRC facilitates use of diagnostic and treatment services by setting up laboratories and strengthening staff capacity to manage NCDs at primary health care facilities. We work in diverse settings, from fragile contexts serving internally displaced and conflict-affected communities in Democratic Republic of Congo, South Sudan, Myanmar, Libya, Yemen, Central African Republic, Nigeria, Syria and Somalia, to long-standing Syrian, Burmese, Somali, Sudanese and South Sudanese refugee populations in camps in Chad, Jordan, Thailand, Tanzania and Kenya, to acute onset refugee situations in Colombia, Uganda and Bangladesh. The IRC works within contexts that experience cyclical shocks and crisis. The path from emergency to recovery is non-linear and often requires development and humanitarian efforts at the same time. The IRC therefore carries out the direct implementation of service while strengthening the capacity of host-country institutions to provide quality services to affected communities.

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
The IRC hopes to share experiences of working on Diabetes treatment and care within humanitarian contexts, and to learn about the experienced of other organizations. humanitarian contexts, and to learn about the experienced of other organizations.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
We are working to increase accessibility of insulin and diagnostic tools in humanitarian context.

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy
The IRC aims to promote the adoption of healthy behaviors at the individual, family and community level that can prevent disease and the need for treatment, particularly in more stable
settings. We integrate NCD care and support into community health programs; we link individuals living with NCDs and their families with economic opportunities to ensure the costs of prevention and treatment do not overwhelm limited family resources; we provide individuals with the skills to prevent NCDs and adhere to treatment; and we work with communities to foster an enabling environment for patients to adopt healthy behaviors.

**Please share any news, work, or events your organization is doing or plans to do regarding research and innovation**

- The IRC is partnering with Johns Hopkins University and Khon Kaen University to examine if the integration of an evidenced-based mental health intervention into existing care for patients with diabetes, hypertension and epilepsy, results in improved health outcomes and reduced costs in refugee camps in Thailand.
- The IRC is partnering with the WHO and Ministry of Health to evaluate the usage, limitations and define areas for future adaption of the NCD emergency health kit in Yemen, Libya, Sudan, and South Sudan.
- The IRC is partnering with Massachusetts Institute of Technology and John’s Hopkins University to examine how mHealth can improve NCD care management for refugees in Kenya.
- The IRC recently completed research with the University of Southern California and Jordan University of Science and Technology to investigate and improve a CHW based model for NCD care among Syrian refugees in Jordan.
- The IRC completed research in DRC on the early experiences of integration of NCDs into emergency primary healthcare.

**Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?**

People living with NCDs are more susceptible to severe & fatal COVID-19 infection & associated complications. As part of our response to the COVID-19 pandemic, the IRC adapted its NCD programs to ensure continuous care with limited risk of exposure at facilities by providing people with a 90 day supply of medication when possible, linking patients with the community health system for follow up and support, and utilizing remote/virtual health services to monitor patient conditions.
What is the mission of your organization?
Changing lives today and tomorrow by accelerating life-changing breakthroughs to cure, treat, and prevent type 1 diabetes and its complications.

Describe the type of work your organization/ entity does in the field of diabetes:
JDRF International is the leading global organization funding Type One Diabetes (T1D) research and improvement in clinical outcomes, with a mission to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2 billion in research funding since our inception, and spurred billions more from public and private sector partners to generate a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout are dedicated to advocacy, scientific research, education, community engagement and our vision of a world without T1D

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
Through participation in the WHO Global Diabetes Compact Forum, JDRF plans to help WHO and other stakeholders share and disseminate ideas, information and views that help create a world where the risk of diabetes is reduced and where all people who are diagnosed with diabetes have access to equitable, comprehensive, affordable and quality treatment and care.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
JDRF is strongly committed to working with other organisations, Governments, philanthropists, and industry to help increase access to insulin and other technologies (including strips and diabetes technologies such as sensors and pumps) around the world. This is part of JDRF’s newly formed Global Access Initiative, where JDRF will work with organisations and individuals across and around the world to this end.

In particular, JDRF has developed the first global T1D Index, an assessment and evaluation of the incidence, prevalence, and burden of type one diabetes for every country around the world. This assists in identifying the most challenging access issues and areas, and quantifying the benefit that would be created by addressing these. The T1D Index should be a substantial and important asset to assist and enable the work of The WHO Compact
Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy

JDRF has launched T1Detect, a screening education and awareness program, to arm people with the information needed before and after getting screened for type 1 diabetes autoantibodies. Now that autoantibody testing is available (currently in the US), even those without family history of T1D can begin to find out—before symptoms even occur—if they are at risk of developing T1D. JDRF works with clinicians and health professional peak bodies to help develop and promote information that assists health literacy.

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation

Guided by a strategic plan, JDRF maintains and promotes a global research agenda that identifies, supports, and manages the most promising research likely to help deliver a world without type 1 diabetes. Our research portfolio spans more than 20 countries and brings together the best and the brightest minds, all seeking to find a cure for this disease. In addition to direct research funding, JDRF helps attract hundreds of millions of dollars in follow-on investments by third parties each year.

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?

People with type 1 diabetes have experienced substantial challenges due to Covid, from both greater health impacts if diagnosed with Covid, to supply chain disruption causing challenges with access to essential supplies, to movement restrictions limiting the ability to access necessary health services. This has occurred in varying ways in different countries, but in total has meant a significant impact.

To assist in addressing this, JDRF, along with Beyond Type 1 and others, developed coronavirusdiabetes.org to provide up to date, evidence-based information relevant to people with diabetes about the impact and other important elements associated with Covid-19.
What is the mission of your organization?

Founded in 1973 in Bahrain, the Landmark Group has successfully grown into one of the largest and most successful retail organizations in the Middle East and India. An international, diversified retail and hospitality conglomerate that encourages entrepreneurship to consistently deliver exceptional value, the Group operates over 2,100 outlets encompassing over 30 million square feet across the Middle East, North Africa, India and South East Asia.

Landmark Group has a strong workforce of over 42,000 employees and provides a value-driven product range for the family through its retail concepts: Centrepoint, Babyshop, Splash, SHOEMART, Lifestyle, Max, Shoexpress, Home Centre, Home Box, Emax, UAE’s first food discounter, VIVA and Styli, the Group’s first online-only fashion offering.

The Group is committed to being an employer of choice and has been recognized over the years, recently being named among the top five of Asia’s and the Middle East’s Best Workplaces in 2021 by Great Place to Work®. The Group were also recipients of the prestigious Brandon Hall’s Human Capital Excellence Awards 2021.

Describe the type of work your organization/ entity does in the field of diabetes:

Landmark Group is committed to raising awareness on the management and prevention of diabetes in India and the Middle East. In 2009, we launched our flagship Beat Diabetes Walkathon, bringing together civil society actors to highlight the various mechanisms of diabetes management. The Walkathon has and continues to gain support from the Dubai Health Authority, the Emirates Diabetes Society, the Dubai Sports Council and Dubai Municipality.

As part of our campaign, we promote early testing, getting active and eating healthy. The campaign has touched the lives of over 120,000 participants and 30,000 children who were actively engaged in our awareness and fitness sessions. The next phase of our programme will focus on scaling the impact and reach of our initiatives through meaningful partnerships.

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?

Learning from peers, connecting with partners and understanding the global dynamic of the diabetes pandemic. Further, the Forum will allow us to expand the scope, depth and impact of our work in India and the Middle East.
Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
No information given.

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy
Landmark Group hosts an annual “Beat Diabetes” event which reaches an average of 20,000 participants every year. As part of this event, testing camps are set up before, after and during the event to promote early detection. Fitness activities are also hosted to promote more active lifestyles.
Our reach also covers schools to ensure that children are aware of the benefits of healthy lifestyles and their role in preventing and managing diabetes.

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation
All proceeds from our flagship event, generated through registration fees and contributions from Landmark, are donated to Al Jalila Foundation to fund research on diabetes.

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?
No information given.
What is the mission of your organization?
To improve understanding of and responses to chronic conditions in low, middle and high-income country settings through research, policy and public engagement and teaching.

Describe the type of work your organization/ entity does in the field of diabetes:
We are a group of researchers from multiple disciplines with skills in epidemiology, economics, social and political sciences; and with a strong focus on health systems. We promote addressing chronic NCDs such as diabetes and considering their interaction with other chronic conditions, in particular mental health, and chronic communicable diseases such as TB and HIV/AIDS. We seek to address diabetes and other chronic conditions in an integrated fashion in response to common determinants and responses between them. We work in low, middle and high-income country settings, including transitional settings and vulnerable populations such as humanitarian crises and migrant populations.

Our researchers conduct observational epidemiological studies using large-scale real-world data from across Europe, The Americas, Asia, and Africa to characterize trajectories of diabetes progression, risk factors for onset and major outcomes, risks and benefits of antidiabetic medications, and inequalities by ethnicity and socioeconomic status. Our researchers also draw upon linked electronic health record, genetic and cohort data in the UK Biobank to examine risks of vascular disease, cancer, and dementia across the glycaemic spectrum.

Our researchers lead The Andhra Pradesh Children and Parent Study (APCAPS), a large prospective, intergenerational cohort study in Southern India. One of the key objectives of the APCAPS study is to examine societal and environmental characteristics, linked to urbanisation, to predict levels of risk factors for chronic diseases, particularly diabetes.

Our researchers based at the LSHTM/MRC Unit in Uganda work on the following questions: What is the scale of, and forecast for, diabetes in Africa, and who will be most affected?, Are the physiology of, and risk factors for, African diabetes similar to those in high income countries? How can we intervene to stem the African diabetes epidemic? The team currently lead the Uganda Diabetic Phenotype (UDIP) study. The primary objective of the UDIP study is to describe the metabolic and immunologic profile of newly diagnosed adult patients with diabetes in Uganda in order to fully understand the unique diabetic phenotype of black African patients.

Website: https://www.lshtm.ac.uk/research/centres/centre-global-chronic-conditions
This is a multi-centre cross-sectional study. The data derived from this study will be invaluable in guiding the formulation of optimal diabetes treatment guidelines and targeted preventive strategies for the black African diabetic population.

The UDIP study is contributing to a large scale research bid to generate an evidence base to inform the development of ethnic-specific guidelines for the management of type 2 diabetes by triangulating global data on ethnic differences in diabetes phenotypes and response to antidiabetic treatment. This project will draw on data from electronic health records and cohort studies from eight countries across Europe, Asia, and Africa to determine whether diabetes phenotypes and treatment response differ between people from different ethnic groups residing in the same country, or between people of the same ethnicity residing in different countries. This program of research aims to generate the first-ever like-for-like comparisons between European, south Asian and African populations across Europe, Asia and Africa to determine whether guidelines for the clinical management of type 2 diabetes need to consider ethnic differences in diabetes phenotypes and treatment response.

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?

Our organisation hopes to establish strong partnerships across the globe in the field of diabetes-related research, policy, and interventions. We hope to share our expertise and experience in the conduct of rigorous epidemiological, social science, and policy-related research to benefit global communities.

We also hope to raise the profile of diabetes-related research, particularly across lower and middle income countries and humanitarian settings. We look forward to developing an international network of partner organisations with a shared long-term vision of improving the care of diabetes worldwide.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.

No information given.

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy.

In December 2020 the CGCC co-hosted the 2nd Annual Symposium on Diabetes in Humanitarian Crises with IADA, the International Alliance for Diabetes Action. This was a virtual event held to review the progress that had been made since the inaugural symposium in April 2019, the major global events of the past year that had impacted the humanitarian health agenda, discuss innovative ideas to improve the delivery of diabetes care in humanitarian settings, and plan the
agenda for 2021.

The symposium featured 5 panel discussions, an abstract session and small group breakout discussions with 44 speakers across 18 countries in 5 global regions. Speakers included experts from the International Rescue Committee, Doctors Without Borders, Life for a Child, UNHCR, Clinton Health Access Initiative, International Diabetes Federation and World Health Organization, among others.

In response to the pandemic, the CGCC is hosting a symposium in November titled ‘COVID-19 and Chronic Conditions: What’s next? This two-day, four-part symposium featuring distinguished speakers including academics, clinicians, decision-makers, funders, and journalists, will provide an epidemiological perspective on this pressing issue, as well as exploring impact and innovation in health care services, ways to strengthen health systems, and global health research and policy.

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation

The CGCC hosts quarterly meetings of the Cardiometabolic Research Interest Group (CAMEL). The goal of CAMEL is to increase the profile of cardiovascular disease and diabetes research conducted at the LSHTM and MRC units, promote collaboration across research groups, and strengthen the quality and impact of cardiovascular disease and diabetes research from the LSHTM and MRC units. Activities include regular meetings and seminars to present ongoing projects, provide feedback on proposals and connect with other researchers.

The CGCC website is regularly updated with news, events, publications, blog posts. We have recently launched a new website focused on non-communicable diseases in humanitarian settings. We also send out a quarterly newsletter to centre members and external interested parties about research and policy highlights and events.

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?

The COVID-19 pandemic has impacted the direction of the research activities and priorities of our members. Our members have recently led a study published in the Lancet Digital Health examining the indirect impacts of the COVID-19 pandemic on healthcare utilisation for diabetes and other chronic physical and mental health conditions. The results showed that weekly primary care contacts for these conditions fell significantly after the introduction of lockdowns in March, 2020, and remained below pre-lockdown levels following the easing of physical restrictions. The authors concluded that these reductions were likely to represent a substantial burden of unmet need, with potential implications for subsequent morbidity and premature mortality (Mansfield et al, 2020, https://doi.org/10.1016/S2589-7500(21)00017-0).
Our members are also preparing funding bids to examine the interaction between COVID-19 and diabetes. One bid currently under consideration with the NIHR aims to answer (1) What happens to the health of people with diabetes who survive COVID-19? (2) Does COVID-19 cause diabetes in survivors of COVID-19, or are there other explanations? Our members have also been heavily involved in the development of the OpenSAFELY research platform and activities around COVID-19 and diabetes. Funded by the MRC and the National Core Studies, current and recent projects include 1) examining changes in the rates of cardiometabolic events during the COVID-19 pandemic 2) determining whether certain second-line antidiabetic drugs offer better protection against severe COVID-19 than others, and 3) exploring how long-COVID will interact with diabetes over the longer-term (https://www.opensafely.org/research/).

Participant Profile – Médecins sans Frontières

Website: https://www.msf.org/ and https://msfaccess.org/

What is the mission of your organization?
Médecins sans Frontières (MSF) is a private international association. The association is made up of doctors, other health care professionals, and a number of professions which help in achieving MSFs aims. All of its members agree to honour the following principles: Médecins Sans Frontières provides assistance to populations in distress, to victims of natural or manmade disasters and to victims of armed conflict. They do so irrespective of race, religion, creed or political convictions. Médecins Sans Frontières observes neutrality and impartiality in the name of universal medical ethics and the right to humanitarian assistance and claims full and unhindered freedom in the exercise of its functions. Members undertake to respect their professional code of ethics and to maintain complete independence from all political, economic, or religious powers. As volunteers, members understand the risks and dangers of the missions they carry out and make no claim for themselves or their assigns for any form of compensation other than that which the association might be able to afford them.
https://www.msf.org/who-we-are

Describe the type of work your organization/ entity does in the field of diabetes:
MSF works in over 70 countries worldwide and has been engaged in providing treatment for diabetes care in multiple projects across a number of countries (including Jordan, Lebanon, Iraq, Syria, South Sudan, Democratic Republic of Congo, Tanzania, Kenya, Zimbabwe, and Bangladesh). MSF programs focus on people living in resource-limited, emergency and humanitarian settings. MSF has worked to try and advance access to diabetes care for people living with diabetes by demonstrating simplified models of care and ensuring access to uninterrupted treatment.
In selected projects, MSF has started to introduce new medicines and technologies such as continuous glucose monitoring with the goal of exploring the impact on quality of care. MSF has developed an advocacy agenda linked to its operations to highlight specific needs for people with diabetes and hypertension and, where relevant, is starting assessments for potential interventions to reduce risk factors and to increase physical activity in the communities where we work. For further information on where MSF is providing diabetes care across the movement please see the international activity report and the following links.

https://www.msf.org/international-activity-report-2020
https://www.msf.org/empowering-children-type-1-diabetes-lebanon
https://www.msf.org/south-sudan-bringing-diabetes-treatment-home
https://msf.org.uk/podcast/diabetes-unseen-humanitarian-emergency

MSF has recently published a study to demonstrate the thermostability of insulin in temperatures experienced in LICs with the aim of helping to address the challenging storage requirements needed for insulin use.

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0245372
https://msf.org.uk/article/diabetes-game-changing-research-will-save-refugee-lives

Alongside MSF’s operational commitment to diabetes the MSF Access Campaign works to overcome access barriers to diabetes care, focusing on expanding access to insulin and simplified treatment approaches for hypertension. For further information on the MSF Access Campaign’s diabetes work please see https://msfaccess.org/diabetes.

**What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?**

MSF hopes to contribute their operational and advocacy experience to the forum, and work with other members on strategies to improve diabetes care including in challenging humanitarian settings. Through collaboration with other forum members, MSF will use the opportunity to specifically address the lack of access to insulin through advocating for the role of quality assured biosimilar products, working towards a target price per patient for the bundle of tools needed for insulin-dependent diabetics, and exploring the role of newer diabetes treatments and technologies with a role in simplifying diabetes care. MSF will also collaborate with other forum members at country level to coordinate advocacy towards national governments to attain the objectives outlined in the 2021 WHA resolution on diabetes.

**Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.**

In follow up to the WHA 74 Diabetes Resolution, MSF Access Campaign - in collaboration with Santé Diabète - is developing a dashboard report from a selected number of countries to document the current status of priority asks within the resolution.
Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy
MSF has developed health promotion and health literacy tools for their operational programmes which will be made publicly available.

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation
MSF is continuing to study the use of continuous glucose monitoring in a paediatric population in Lebanon, is exploring opportunities to study the potential benefits of moving to pen and analogue formulations in humanitarian settings and is starting to pilot the use of fixed dose combination therapy for hypertension including for people with diabetes.

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?
The burden of undiagnosed or poorly controlled diabetes has been evident in the patients MSF has treated with severe COVID-19. MSF created diabetes protocols for intensive care treatment of severe COVID-19 patients, adding longer-acting analogues to improve control.
COVID-19 has meant MSF programmes have had to adapt how they deliver diabetes care, reducing the interaction with the health facility. Examples have included increasing the duration of medication provided, community delivery and remote consultations. A number of these interventions that may benefit the health system and people living with diabetes in the longer term will be assessed and continued, if found to have positive impacts.

Participant Profile – Medicines Patent Pool

Website: https://medicinespatentpool.org/

What is the mission of your organization?
Our mission is to increase access to, and facilitate the development of, life-saving medicines for LMICs. We do this through an innovative approach to voluntary licensing and patent pooling. We work with a range of partners — civil society, international organisations, industry, patient groups and governments — to prioritise and license novel and existing medicines and health technologies for people in these countries.

Describe the type of work your organization/ entity does in the field of diabetes:
MPP’s mandate is to accelerate access to affordable quality treatments for people living with HIV, hepatitis C and tuberculosis, as well as HIV-associated co-morbidities. Since 2018, MPP has expanded its mandate to other patented essential medicines on the World Health Organization
(WHO)’s Model List of Essential Medicines (EML) as well as medicines with strong potential for future inclusion on the EML. This includes essential medicines for diabetes such as SGLT2i. In these last two years, MPP engaged with several organisations working in diabetes, such as the International Diabetes Federation, and drugs originators, to build the case for voluntary licensing.

**What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?**
Liaising with additional partners to maximize efforts for an improved and affordable access of patented diabetes medicines (such as SGLT2i) in LMICs.

**Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.**
MPP is working, also with other partners such as the International Diabetes Federation, to improve affordable access to patented essential medicines for diabetes.

**Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy**
No information given

**Please share any news, work, or events your organization is doing or plans to do regarding research and innovation**
No information given

**Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?**
No information given
Participant Profile – NCD Alliance

What is the mission of your organization?
X

Describe the type of work your organization/ entity does in the field of diabetes:
X

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
X

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
X

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy
X

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation
X

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?
X
What is the mission of your organization?
NCD Child is a global multi-stakeholder coalition championing the rights and needs of children, adolescents, and young people who are living with or at risk of developing non-communicable diseases (NCDs). The mission for NCD Child is to ensure that issues related to NCDs are addressed and prioritized in national, regional and global policies. Above all, these policies should center around children, adolescents, and young people. Furthermore, we work to ensure the voices of young people and families are heard in all settings where policies, systems or programs are developed and implemented.

Describe the type of work your organization/ entity does in the field of diabetes:
• Advocate for the inclusion of children, adolescents, and young people in the global non-communicable diseases (NCDs) agenda, including participation in the diabetes movement
• Contribute to, and develop evidence-based resources related to NCD prevention and control including diabetes
• Develop learning materials on how to effectively advocate for improved prevention and management of NCDs among young people, including diabetes
• Support youth advocates to ensure their meaningful and sustained engagement in global, regional, and national NCD spheres, including representation of young people living with diabetes in the Young Leaders Program
• Advocate for improved access to essential medicines and equipment, including insulin and diabetes supplies, through the Taskforce on Essential Medicines and Equipment

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
We aim to ensure that the needs, views and voices of young people are included in the WHO Global Diabetes Compact Forum. We believe that in order to effectively reduce the risk of diabetes, and ensure that all those with diabetes have access to quality care, that the participation of young people is vital.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
• Members of the Taskforce on Essential Medicines and Equipment are contributing to a revision of the WHO EMLc for more inclusive and broad coverage of insulin and equipment related to diabetes care.
Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy

- We have launched an online campaign called #YouthBeyondT1D to highlight the perspectives of young people living with type 1 diabetes including management of the disease through self-care and peer support measures
- We are planning to create a documentary video to bring forth solutions and peer support resources for young people with T1D, and to build an online repository of helpful resources.

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation

- We are planning to publish a review article on global access to medicines and equipment for diabetes care, with a focus on type 1 diabetes in LLMICs, including the impacts of the COVID-19 pandemic
- We are planning to create a practical roadmap for integrating NCD prevention and control across delivery platforms for children and adolescents, including diabetes.

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?

Several young people who responded to the #YouthBeyondT1D campaign highlighted challenges to equitable and consistent access to medicines and supplies for diabetes care. Excerpts include:

"Some challenges of living with T1 diabetes are dealing with the fact that even tough after 100 years of the discovery of insulin, there are still people dying due lack of access to care, access to treatment, access to information and access to support." (Brazil)

"Some of challenges of living with T1 diabetes are to have fight with during our whole live with a silent condition, that not always will wake up 'wishing you good morning'. A condition that in Brazil, still demands constant fight for access to diabetes supplies." (Brazil)

"Fight eternally with the social works to have the necessary supplies for the day to day up to date. For example insulin, lancets, strips, as well as pump supplies." (Argentina)

"Inaccessibility and unaffordable of Medication: In my country, mostly of youth living with T1 Diabetes cannot afford buying insulin and Lack of right T1 Diabetes Education, Having or living with T1 Diabetes is one thing but knowing how to living with it another thing that is challenging youth living with T1Diabetes." (Tanzania)

"Living with T1 diabetes challenges include inaccessibility to medication, deliverables and tests, limited resources for procurement of the same, lack of proper education on T1 management and
inadequate healthcare personnel." (Kenya)

"High cost of diabetic medication, i.e insulin, lancets and blood glucose monitoring equipment. Unsupportive environment such socialization, stigma, schools, colleges, meal plan. Wide spread myths and misconception undermining effective self-management. ie signs and symptoms treatment." (Kenya)

"Living with Type 1 Diabetes isn't as easier as it seems. To manage Type 1 Diabetes 24×7 becomes"

**Participant Profile – NGO Santé Diabète (Association Santé Diabète)**

**Website:** [www.santediabete.org](http://www.santediabete.org)

**What is the mission of your organization?**

Santé Diabète is a Non-Governmental Organization founded in 2001 to respond to the lack of access to healthcare for people with diabetes in Africa and to the failure to take this health emergency into account by development actors at the global level. First present in Mali, Santé Diabète then expanded its programs to Burkina Faso, the Comoros as well as in France (headquarters of the association) with permanent teams in each country and a network of more than 200 local and international partners. With a team of 40 people and more than 200 local and international partners, Santé Diabète acts every day in countries to save lives through prevention and diabetes management programs that aim to improve the quality of life of people affected by this chronic disease.

**Describe the type of work your organization/ entity does in the field of diabetes:**

The intervention of our NGO focus on a comprehensive approach including on all the aspects to implement quality prevention and management of diabetes. THIS INNOVATIVE APPROACH TRANSLATES INTO PRACTICE BY THE ESTABLISHMENT OF 6 COMPONENTS:

1. **PRIMARY PREVENTION**
   - to reduce the human and economic burden of the progression of the disease

2. **decentralization of care**
   - to guarantee the geographical accessibility of the populations to quality care

3. **SECONDARY AND TERTIARY PREVENTION / THERAPEUTIC LITERACY/EDUCATION**
   - to reduce the burden of complications from diabetes

4. **REDUCTION OF CARE COSTS**
   - to make it possible for populations to access diabetes care
5. Integrated approach
including active participation of patients and their families by supporting patient associations,
self-management and advocacy mechanisms
6. Research to develop innovative approaches in the research / diabetes sector

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
To share our expertise and learn from other organizations

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
We led the coalition of civil society actors for the adoption of the insulin resolution / we lead many other advocacy actions around access to insulin.

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy
We organized important program of prevention by media, in the communities, in school.

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation
We are leading a lot of research (ACCISS on access to insulin, Health Literacy, therapeutic education)

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?
Yes and we developed a response covid19-Diabetes in Mali and Burkina Faso
1 - International advocacy strategy
• Through a coalition of 22 international organizations led by LFAC,
Santé Diabète carried out an action to the aims of:
Identifying shortages of insulin and other essential diabetes supplies (syringes, blood glucose strips, oral anti-diabetics, etc.), as well as other difficulties in diabetes care, which result from the disruption caused by COVID-19.
Mobilizing support and share best practices in order to best meet these needs.
2 - Strategy implemented in Mali and Burkina Faso (then in Union of the Comoros)
A - National technical assistance
• In these countries, Santé Diabète will develop technical assistance to the Ministries of Health in order to support them to ensure:
• Adequate distribution of the resources of the health system to ensure quality care for patients with chronic diseases;
• Work with the government to ensure that the stocks of drugs are sufficient so as not to have a national shortage

B - Prevention in people with diabetes

Produce prevention video at national level
SMS campaigns sent to people with diabetes who are members of patient associations in the capitals but also in regions of different countries
Provide patients wishing to use two WhatsApp exchanges with specialists in diabetes or endocrinologists to carry out teleconsultations to enhance prevention and better monitor the progress of the chronic disease, while avoiding traveling around health structures.
Training of patient associations and distribution of masks and hydroalcoholic solutions (SHA) for patients with diabetes in partnership with MSF;
In Mali the possibility of providing continuity of care at home with the nurses of the «Santé Mobile» company and to provide supply of medicines (insulin, syringes, antidiabetics, etc.) for indigent patients with diabetes and infected with COVID
**Participant Profile – PATH**

**Website:** [www.path.org](http://www.path.org)

What is the mission of your organization?
Our mission is to advance health equity through innovation and partnerships.

Describe the type of work your organization/ entity does in the field of diabetes:
Through partnerships and collaborations with MOHs, PATH has been working in NCDs for more than 20 years, starting with work in breast and cervical cancer and expanding to diabetes and cardiovascular risk in 2012. PATH’s NCD Program’s focus areas include: 1) Strengthening primary health care to reach people where they live with awareness, screening, early diagnosis, and treatment; 2) NCD prevention through school health and workplace wellness; 3) Implementation of digital solutions and innovative models of service delivery including engagement of community health workers, social enterprises, and private-sector partnerships; 4) Awareness raising and interventions at the national, regional, and global levels toward ensuring continuous access to high-quality medicines and health products for NCD care.

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
We look forward to participating in discussions, information exchange, and innovation that can lead to improved access to care, improved quality of life, and improved health outcomes for people living with diabetes.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy
No information given.
Please share any news, work, or events your organization is doing or plans to do regarding research and innovation
No information given.

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?
No information given.

---

**Participant Profile – Positive on Glucose**

**Website:** N/A

**What is the mission of your organization?**
To share knowledge and connect people, and to improve the quality of life of the people living with diabetes through education, coaching, a support network, and advocacy to support people living with this condition

**Describe the type of work your organization/ entity does in the field of diabetes:**
The organization orchestrates weekly diabetes support group sessions, advocacy training, diabetes education from a holistic approach, support sessions for caretakers of people living with diabetes, collaboration with local actors to educate and support elderly community members and educate them about their conditions, collaboration with hospitals to provide donated diabetes medication and supplies

**What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?**
People living with diabetes have the right to live a noble and healthy life. They deserve to have access to information and medication. Through the forum, I am certain that we will be able to come together with other International actors and be vehicles for change and a better lived life with this condition. Through out experience, expertise, and willingness to be a vessel of change, I hope that we can come together and synergies action for a better future with less complications.

**Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.**
Below are some links to work we’ve done in the past.
Some of our more recent work was extensive meetings with the ministry of health to continue the subsidization of free style Libre sensors which was positive and is a major win as they are still priced at the 1500 LBP rate and not the 20,000 LBP black market rate.

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy
We are currently attending the ISPAD2021 conference and plan to create our event in collaboration with another international NGO in Egypt in November.

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation
https://docs.google.com/document/d/1RIHiEqdBWUTsWfsWRphmXlK964onb9unUj6a2GVM3SU/edit?usp=sharing
This is a survey we did along Nation Station in Geitawi are to understand how widespread diabetes it, how people are coping and what is needed in terms of medication and psychosocial support.

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?
Unfortunately, yes. Overall the COVID-19 pandemic hit Lebanon hard, in parallel with one of the worst economic crisis the world has seen in the last hundred years. This means that even after COVID, people will still struggle to access their most basic care in terms in diabetes in particular and NCDs in general. Mainly, some insulin brands are scarce and even out of the market. Others are available at black market rate and would literally cost a paycheck just to buy a box of insulin.
In terms of checkups, hospitals have increased their admission prices and doctors are immigrating. I wish this only had to do with the COVIS-19 pandemic. Unfortunately, this is deeper and bigger and needs a lot of attention. If this crisis is not handled, the price cap of complications resulting from poor diabetes management will be severely high.

Participant Profile – Primary Care International

Website: https://pci-360.com/

What is the mission of your organization?
We build capacity in people and primary health care systems by:
• Training health care workers to deliver evidence-based care adapted to local contexts
• Working with people to develop their strategic and organisational approach to care, and to train others
• Using a Family Medicine approach with a focus on Non-Communicable Diseases

Describe the type of work your organization/entity does in the field of diabetes:
PCI supports quality of care for managing chronic diseases at primary care level in low- and middle-income countries.

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
Share the experiences of the partners and primary care healthworkers we work with, and ensure management of diabetes and the package of support needed is considered by policy and decision makers

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
No information given.

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy
No information given.

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation
No information given.

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?
Yes, COVID-19 has affected our partners and the healthworkers we work with in a number of ways. Border closures have meant lack of access to medicines. Fear of covid has meant clinics are seeing fewer patients - they are visiting primary care centres less and not getting their check-ups or medication. Covid related lockdowns have also meant incomes have been affected and in some cases people can’t afford the medicines they need.
What is the mission of your organization?
To support oral health education and prevention for people living with diabetes.

Describe the type of work your organization/ entity does in the field of diabetes:
Organising free oral screening for patients with diabetes in Hungary.

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
To support oral health prevention!

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
We support local and international NGO's with our research activities!

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy
Organising free oral screening for patients with diabetes in Hungary since 2015!

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation
We support local and international NGO’s with our research activities!

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?
No information given.
What is the mission of your organization?
To promote the science and practice of Public Health and preventive medicine in the field of cardio-metabolic renal medicine
To conduct regular meetings to promote continuous professional development in cardio-metabolic renal medicine for all health professionals (conducted virtually on every month)
To work with NCD alliance and non-governmental organizations for promotion and enabling health and wellness across the life course
To work with NCD alliance and non-governmental organizations to ensure people living with diabetes receive integrated people-centred health services to prevent and control NCDs+

Describe the type of work your organization/ entity does in the field of diabetes:
Department of Community & Family Medicine, All India Institute of Medical Sciences, Gorakhpur deals with Health promotion, prevention, curative and rehabilitation services of Diabetes and other non-communicable disease.

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
To establish link with other international organizations to share and to disseminate ideas, information and views that help in advocating for the vision the Global Diabetes Compact.
To learn from other forum members how they overcome challenges in their own settings and to develop case studies on the experiences to be used for experiential learning
Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
The members of the South African Public Health and Preventive Medicine Association (SAPHPMA) work closely with the Department of Health for easy access to insulin and insulin analogues at primary health care. The SAPHPMA and South African Medical Association partnered with Southern African Health Technology Assessment Society for optimal use of health technology at community level.
Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy

The members of SAPHPMA work closely with the South African Medical Association and Department of Health and established a Preventive medicine task force for creation of evidence-based prevention guidelines. One of the Working Group of this task force focuses on Cardio-metabolic renal medicine.

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation

One of the members participated as a Ministerial task team member for drafting the National strategic plan for the prevention and control of non-communicable diseases 2021-2026

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?

The members of SAPHPMA are public health physicians. Many of them actively participated in management of COVID-19 patients. The access to drugs and other consumables were not found to be a major problem in South Africa.

Participant Profile – Staffordshire University

Website: www.staffs.ac.uk

What is the mission of your organization?

We are the Connected University. We’re connected to the needs of our students, to business and to society. Our industry connections and emphasis on experience make our graduates among the most employable in the UK. Our gold award in the 2019 Teaching Excellence Framework recognises excellent standards of learning and teaching, while 78 per cent of our research is world-leading or of international importance (Research Excellence Framework 2014). Our interdisciplinary network of research centres drive the publication of hundreds of papers each year.

Describe the type of work your organization/ entity does in the field of diabetes:

The Centre for Biomechanics and Rehabilitation Technologies (CBRT) at Staffordshire University is made up of a vibrant group of researchers led by Professor Chockalingam, who is an internationally recognised researcher in the area of foot and footwear biomechanics. Improving health, quality of life and healthcare provision by solving complex biomechanical issues is the focus of the CBRT’s research. This is delivered through highly innovative and integrated inter, and
multi-disciplinary approaches in areas related to diagnosis, prognosis, prevention and intervention related to diabetic foot disease. Research themes include medical engineering, computational biomechanics, biomechanical analyses and tissue mechanics. The team leads systematic reviews and conducts clinical trials for technology assessment around diagnostics and prescription, and has delivered WHO funded work on Prosthetics and Orthotics. The CBRT has produced over 150 high quality and impactful outputs and published in over 50 different journals reflecting its multidisciplinary interests. As evidenced by a growing number of citations, these outputs and the multidisciplinary research interest is developed organically through international collaborations focused on translational research (over 45% of CBRT’s publications are internationally co-authored).

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
The key strength of the CBRT is being truly interdisciplinary (Computational Biomechanics, Mathematical Modelling, Experimental Biomechanics) and multidisciplinary (Clinical Biomechanics, Tissue Mechanics, Clinical Sciences, Physiology) and contributing to a supra-disciplinary area of biomechanics and human movement. The CBRT at Staffordshire is something unique, which focuses on translational research and industry collaboration. The Centre’s strength is also reflected in its international links and the academic and clinical reputation of the staff. Through participation in the WHO Global Diabetes Compact Forum, we would like to influence policy and practice relating to the clinical management of diabetic foot complications.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
https://theconversation.com/preventing-a-million-diabetic-foot-amputations-90257

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation
http://www.diabsmart.eu/

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?
Not applicable.
What is the mission of your organization?
HAI’s vision is a world in which everyone, everywhere, has access to safe, effective, affordable and quality-assured medicines. To make our vision a reality, the mission of our staff, members and partners is to create lasting change to government and industry policies and practices through research, evidence-based advocacy, and public awareness initiatives at national, regional and international levels.

Describe the type of work your organization/ entity does in the field of diabetes:
Since its inception in 2015, HAI’s Addressing the Challenge and Constraints of Insulin Sources and Supply (ACCISS) Study has been working to identify and address the inequities and inefficiencies in the global insulin market. We work in partnership at the global and national levels to advocate for improved access to insulin, diagnostics and care.

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
To ensure that access to insulin and diagnostics remain a priority for the Diabetes Compact and to provide guidance for evidence-based interventions where applicable.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
ACCISS Study’s focus is on access to insulin and health technologies. Over the past 7 years we have created a global evidence-base on the topic. You can view our resources here:
https://accisstoolkit.haiweb.org/publications/
In Fall 2021 we have released the following publications and videos around access to insulin and diagnostics Video: Access to INSULIN 100 Years On | Leaving No One Behind
https://www.youtube.com/watch?v=J9REgHwcsGc
Market Report on Self-monitoring Devices in Low- and Middle-Income Countries:
https://accisstoolkit.haiweb.org/evidence/diagnosticresearch
Global Estimate on Type 1 Diabetes:
https://link.springer.com/content/pdf/10.1007/s00125-021-05571-8.pdf

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy
No information given.
Please share any news, work, or events your organization is doing or plans to do regarding research and innovation
No information given.

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?
Our partner CRONICAS in Peru, which is a country with a high COVID prevalence, is currently finalizing a report that was conducted during the pandemic to see what impact the virus had on people living type 1 diabetes to accessing insulin and care. The report will be published when finalized.

COVID-19 impacted access to care in other countries where we work. For example, in Kyrgyzstan the management of type 1 diabetes is predominantly undertaken in the capital Bishkek. Under lockdown, where travel was severely restricted, and health professionals in Bishkek were stretched to capacity, people living outside of Bishkek had been unable to travel for appointments with their endocrinologist.

This meant gaps in care for many. Prior to lockdown, our partner HPAC had started training family doctors on diabetes care in regions outside of the city to help ensure a continuum of care for people living with diabetes. The events of the past few years has pressed upon how essential this work is to continue and to expand to other health care workers.

**Participant Profile – Sweet Life Diabetes Community**

**Website:** N/A

**What is the mission of your organization?**
X

**Describe the type of work your organization/ entity does in the field of diabetes:**
We are South Africa's largest online diabetes community, and our focus is on diabetes education that truly connects with people living with diabetes in South Africa. We are a registered NPO with a single focus: to improve diabetes in South Africa.
Sweet Life is a diabetes community that informs, inspires and connects people with diabetes in South Africa. Get expert advice on all you need to know about diabetes and join a community of Diabetic South Africans. Just because you have diabetes, doesn’t mean you can't live a happy, healthy life.
As a registered NPO (220-984), our goals are:
To improve the diagnosis number in SA (at the moment 1 in 2 people with diabetes
are undiagnosed)
To improve the health of people with diabetes in SA by encouraging TEEL:
Take your medication
• Eat healthy food
• Exercise, a little every day
• Lose weight, if necessary.

Our focus is on simple, easy-to-understand information for Diabetic South Africans.
Diabetes isn’t just a medical condition. Our team includes top diabetes experts in South Africa.
These diabetes experts help us to provide you with reliable, relevant and medically accurate diabetes information.

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
We hope to collaborate with other diabetes organisations around the world, learning from and contributing to the discussion on how best to solve diabetes education and how to better advocate for the rights of people living with diabetes in South Africa.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
We have been working with SA Diabetes Advocacy (which we co-founded) on a #cgm4all campaign, to try and get access to diabetes technology for more South Africans.
You can find out more here:
https://diabetesadvocacy.org.za/2020-cgm4all-campaign/

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy
We are currently working on a Wear Blue for Diabetes campaign that will send a Type 1 diabetes video and resources on living with Type 1 diabetes, symptoms of diabetes, and education around diabetes into over 3000 schools around the country. Information will shortly be up on www.sweetlife.org.za/community

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation
We are integrally involved in South Africa’s inaugural Diabetes Summit, from which a Diabetes Strategy / Action Plan will be produced (the first of its kind) and shared with the National Department of Health, and members of parliament. You can find out more at https://www.diabetesalliance.org.za/diabetes-summit/
Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?

COVID-19 adversely affected many people with diabetes in South Africa. Challenges are faced by both patients and the health system: patients are not empowered to make informed decisions around diabetes prevention and management. Nurses are overburdened and short-staffed; they may not have time to address health questions posed by people with diabetes or may require additional support to better serve their patients. These challenges have been significantly compounded by the COVID-19 pandemic and, given the greater risk of fatality for patients with diabetes (diagnosed or undiagnosed) who contract COVID-19, the urgency of the need for innovation and digital support has never been more evident.

Access to public clinics was curtailed by strict lockdowns and people living with diabetes being reluctant to venture out to pharmacies or clinics for supplies. There was a lot of fear around COVID-19, and a lot of misinformation. We countered this with a special library of COVID-19 information specifically for PLWD in South Africa.

Find out more at https://sweetlife.org.za/category/community/covid-19/

Participant Profile – T1International

Website: https://www.t1international.com/

What is the mission of your organization?
We support local communities by giving them the tools they need to stand up for their rights so that access to insulin and diabetes supplies becomes a reality for all.

Describe the type of work your organization/ entity does in the field of diabetes:
We provide people living with diabetes worldwide the resources and training they need to advocate for access to insulin and diabetes treatment supplies in their own countries and communities. We do this through four foundational pillars: 1) We raise awareness of type 1 diabetes (T1D) issues and share the voices of people living with T1D around the world; 2) We work toward a higher standard of research, data and statistics about the issues faced by those with T1D; 3) We act as a knowledge hub, providing and signposting to key information and resources related to T1D; 4) We campaign for systemic and sustainable change for people with T1D globally.
What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
We hope to influence the content and tone of media around World Diabetes Day to hold pharma and industry accountable for the insulin access crisis. Furthermore, we hope to bring the voices and perspectives of people living with diabetes around the world to the WHO’s Global Diabetes Compact Forum, so that patient representation is truly included in the direction of the Compact.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
We recently advocated successfully for the addition of long-acting insulin analogues to the WHO EML. We also submitted commentary, informed by our community of global advocacy volunteers, related to the Global Diabetes Compact goals and metrics. We are constantly working on digital campaigns, virtual trainings, and resources for our community of volunteers to help them influence policy, education, and awareness related to insulin access and other diabetes issues in their local communities.

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy
We aim to have our advocacy resources, trainings, digital demonstration posts, and workshop content translated into as many languages as possible. We typically let our order of priority be dictated by languages spoken by those in our global advocacy network at any given time. We are working to expand the accessibility of our trainings, meetings, and workshop content through captioning. We offer video tutorials when applicable to increase accessibility for those with reduced literacy. We prioritize mental health in our messaging and work to represent the mental health needs of people living with diabetes.

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation
Most recently, we have published our study, Costs and underuse of insulin and diabetes supplies: Findings from the 2020 T1International cross-sectional web-based survey,’ in Diabetes Research and Clinical Practice. We carry out an out-of-pocket cost survey every two years.

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?
Our stakeholders, being for the most part people living with diabetes who lack adequate access to insulin and other essential diabetes medications, have absolutely been impacted by the COVID-19 crisis. For example, lockdowns in Tanzania, Pakistan, and other places where our global advocacy volunteers live and operate have prevented many families from accessing their diabetes supplies, healthcare, and education as usual.
What is the mission of your organization?
Provide therapeutic patient education for patients with chronic diseases, in particular diabetes, obesity and associated conditions, in order to prevent complications.

Describe the type of work your organization/ entity does in the field of diabetes:
The unit makes it possible to integrate all the facets of fundamental, clinical and psycho-educational research. They are applied directly to patients in order to improve their quality of life and treatment adherence, and to reduce their complications. In this sense, the unit offers innovative multidisciplinary research unique in its diversity and clinical application.

The teams have been working in the field of diabetology and obesity research for more than 25 years to better understand the mechanisms of resistance to weight loss today. Research carried out in the field of metabolism has thus made it possible to discover that we are not "equal in terms of calories", due to energy savings, a defect in the regulation of the autonomic nervous system and insulin resistance. This resistance to weight loss is also being studied to improve behavior changes in the field of psychology, pedagogy and even in art therapy. Motivation to change behavior is a major difficulty in the clinic, and the research carried out by the unit is also making it possible to innovate in new psycho-pedagogical approaches. Another aspect of research is the diabetic foot, in particular with the collaboration of EPFL Lausanne.

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
Contribution to the development of new guidelines for diabetes management, with special emphasis on therapeutic patient education. Promotion of research in that field in low and middle income countries

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
No information given.

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy
Not Information given.
Please share any news, work, or events your organization is doing or plans to do regarding research and innovation
Not Information given.

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?
No information given.

Participant Profile – University of Pretoria, Department of Public Health Medicine

Website: [https://www.up.ac.za/public-health-medicine](https://www.up.ac.za/public-health-medicine)

What is the mission of your organization?
To become an internationally recognised centre of excellence for Public Health and Preventive Medicine through provision of Preventive Promotive care

Describe the type of work your organization/ entity does in the field of diabetes:
We are involved in guideline development (South African National Strategic Plan on NCDs), screening of Diabetic patients, treatment guidelines, health care worker training and monitoring and evaluation of programmes implemented at the primary health care level.

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
We hope to develop collaborative plans, share knowledge, implement research and develop effective prevention and treatment plans for people living with Diabetes. We also want to advocate for development of community and primary health care level plans aimed at preventing the development of Diabetes and addressing the social determinants of Diabetes.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
Use of bioelectrical impedance tools to screen for Ischaemic Heart Disease
Use of telemedicine to connect primary and tertiary levels of Diabetic care
Use of mobile application technology to monitor patients living with Diabetes
Introduction of newer diabetic agents in treating poorly controlled patients living with Diabetes.
Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy

- Preventative medicine curriculum training
- Implementation research training on non-communicable diseases
- Community orientated primary care for Diabetes
- Development of national guidelines on non-communicable diseases using evidence-based medicine

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation

We are currently in phase 1 of an integrated approach to cardio-metabolic-renal medicine which includes multidisciplinary teams in three districts in Gauteng province.

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?

COVID-19 has left lasting imprinting on the South African health care system. In the Tshwane district - we increased access of medication to patients by introducing home delivery of medication. However, we were unable to monitor glycaemic control remotely. We are now monitoring patients who attend the facility to determine control vs. poor control. Furthermore, we were unable to screen patients with Diabetes due to decreased utilisation of primary health care during the lockdown. We also had to shift services away from elective procedures at hospitals and now face backlogs in surgery and ophthalmology which could relate to complicated Diabetic cases.
What is the mission of your organization?
The mission of Diabetic Association of Pakistan is to provide specialised Medical Care and Education to the people with diabetes. Provide total healthcare including rehabilitation for all diabetics irrespective of gender, economic and social status through different institutions of Diabetic Associations of Pakistan. Develop leadership in healthcare through dedicated and transparent management system. The DAP strives to help the people with diabetes and those who are at risk of developing it by providing innovative patient care, diabetes education and related services with the hope of improving the overall quality of life for those who are affected.

Describe the type of work your organization/ entity does in the field of diabetes:
Diabetes Association of Pakistan aims to establish and promote awareness of diabetes and its prevention throughout the population. The DAP mission is to encourage healthy lifestyle adaptations which will help reduce the risk of its diagnosis in the future. The Diabetes Association of Pakistan (DAP) provides education, training and support for the patient with diabetes or is at risk of getting it. Some of the services we offer at DAP:

- Diabetes and dietetic education and support
  - Foot clinic
  - Retinal camera
  - Healthy Kitchen
  - Insulin pump support and education

DAP works with the patients, their families and their schools or workplace in order to make their surroundings diabetes safe, healthy and supportive. DAP also works with their health care professional to improve and update their knowledge which will in turn help improve the patients’ care management plan.

We have many community outreach programs, such as:
- Diabetes awareness programs at Schools and workplace
- Family activities, Walkathons and community assessment of diabetes or its risk
- Programs to support the newly diagnosed patients
- Diabetes Prevention Camps
- Regional Children with Diabetes Camps –Al Bawasil Camp
- Adolescents with diabetes camp- Al Tahadi Camp
What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?

We shall be able to liaise with the policy makers
We shall be able to implement National level guidelines for the management of diabetes
Advocacy for Diabetes Registry of Pakistan (DROP)
Linkages with International stakeholders to broaden the canvas of Research Work

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.

In collaboration with Life for a Child Program and Direct Relief “Insulin My Life program” (IML) is supporting free of cost insulin, glucometers, strips and HbA1c testing to 2000 plus type 1 subjects. Another program “Changing Diabetes in children” has started its work for the free of cost access of insulin and other essentials of care.

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy.

A project on Primary Prevention of diabetes is recently applied in GCF funding program of Higher education Commission (HEC) of Pakistan Annual Walk, Seminars and conferences are being arranged regularly on prevention and awareness of diabetes

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation

235 research publications done
30 plus research papers are in process of publication
50 plus research projects are in different phases of execution

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?

Our Organization has not been directly affected through COVID-19 Pandemic with respect to access to insulin, diabetes supplies and other elements of diabetes care. Number of patients approaching for the care were affected at the time of the peaks.
What is the mission of your organization?
To achieve proper prevention and management of Diabetes in the region

Describe the type of work your organization/ entity does in the field of diabetes:
M V Hospital for Diabetes situated at Royapuram, Chennai was established by late Prof M Viswanathan, Doyen of Diabetology in India, in 1954 as a general hospital. In 1971, it became a hospital exclusively for diabetes care. Under Prof M Viswanathan's professional and administrative leadership, the hospital has grown to achieve the status of a teaching institution of international excellence. The hospital along with the Diabetes Research Centre undertakes research and imparts post-graduate training in diabetology to doctors. Over the years it has grown to be one of the largest referral centres for diabetes with 3,50,000 registered patients to date. The centre is designated as the World Health Organization's collaborating centre for Research, Education and Training in Diabetes. The terms of references of the centre include TOR1: under WHO leadership conduct epidemiological research on prevention and identification of predictors of diabetes and its complications and its associated co-morbid conditions of public health importance. TOR2: To strengthen education and training in diabetes research, prevention and management. TOR3: To develop methods for reducing diabetes risk factors at the community level. The current activities for the terms of references include TOR1: Trends in rates of lower-limb amputation rates in people with diabetes. TOR2: Training for community health workers on prevention and non-medical management of diabetes in primary care. TOR3: A review of the published interventions to prevent diabetes in low income settings.

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
Creating awareness among high-risk individuals, treatment and management of diabetes, advanced research in the field of diabetes and its complications like diabetes foot, kidney, epidemiology, genetics, diet and prevention. Dissemination of new technologies, research and innovation in the field of diabetes. Strengthening stakeholder engagement in the delivery of diabetes care, health promotion, prevention and awareness of diabetes. The centre is designated as the World Health Organization's collaborating centre for Research, Education and Training in Diabetes. The terms of references of the centre include TOR1: under WHO leadership conduct epidemiological research on prevention and identification of predictors of diabetes and its complications and its associated comorbid conditions of public health importance. TOR2: To
strengthen education and training in diabetes research, prevention and management. TOR3: To develop methods for reducing diabetes risk factors at the community level.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.

RSSDI
D Foot international

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy

Every year, on world diabetes day (14th November), MV Hospital for Diabetes and Prof M Viswanathan Diabetes Research Centre creates awareness to the public by the blue lightning ceremony in public places. Education to the offspring of the registered patients on risk factors, preventive measures for diabetes. Training programs for community health workers, nurses, other paramedical staff and doctors.

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation

Research conducted under various departments like epidemiology, primary prevention, diet, kidney, foot and molecular genetics.

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?

No information given.
What is the mission of your organization?
Having role as one of the highest ranking medical research entities in Iran, the Endocrinology and Metabolism Research Institute (EMRI) has remained at the vanguard of building and strengthening research culture and conducting clinical and basic medical sciences research projects. Moreover, it has played a key role in heightening public awareness, professional education, and provision of clinical services in the field of non-communicable disorders with a focus on diabetes, osteoporosis, and metabolic diseases.

Describe the type of work your organization/ entity does in the field of diabetes:
EMRI is an interdisciplinary research facility in the field of endocrinology and metabolism, including diabetes, and provides a multifaceted approach to restore patients’ health through forging collaboration amongst different basic, clinical, and population-based sciences.

A.1. Activities on Diabetes Research:
Conducting Multi Center Studies with cooperation of Iranian medical Universities (Shiraz, Mashad, Esfahan...)
- Organizing Iran Diabetes Leadership Forum
- Conducting NCD diseases project in the city of Ghazvin, in cooperation with WHO
- Conducting National project on Gestational Diabetes Mellitus.
- Close cooperation with prestigious world universities and research centers to conduct joint projects. Strong collaborations exist between his department and the department of endocrinology of University of Tennessee, University of Alberta, University of Toronto and Mayo clinic as well as Oxford University and the Harvard University.
- Collaborating with NGOs to support patients with diabetes
- Conducting research on new therapeutic approaches on diabetes e.g. Islet Transplantation Projects

A.2 Activities on Diabetes Education:
Public and professional education at EMRI encompasses a wide range of activities including capacity building of health care professional through organizing professional training sessions, fellowship, PhD by research, clinical physician, and sabbatical programs.
EMRI has also played a great role in education of medial students at different stages of medical training, from basic sciences to endocrinology fellowship. Besides academic education, the Institute has effectively contributed to ongoing training programs through design and
implementation of various accredited workshops and training courses for medical graduates and nurses who wish to update their knowledge on different endocrinology-related subjects with a special focus on diabetes and diabetic foot. Many of such training courses are conducted in collaboration with globally-renowned academia and organizations such as World Health Organization (WHO), International Diabetes Federation (IDF), International Working Group on the Diabetic Foot (IWGDF), and International Osteoporosis Foundation (IOF).

As the Director and Chief Scientific officer of the EMRI, Dr. Larijani has been involved in:
- Organizing Comprehensive Courses on Diabetes Management for Physicians
- Organizing Diabetic Foot Workshop for nurses and physician all across the country
- Supervising +150 Thesis on different aspects of Diabetes (including different Postgraduate levels, i.e. Doctor of Medicine, Internal Medicine, Fellowship in Endocrinology, and PhD degrees)
- +50 books edited or translated in different aspects of diabetes/
- Publication of +800 articles on diabetes in peer-reviewed medical journals (national/ International)
- Establishment of Diabetes Virtual Clinic
- +300 workshops, national seminars, and also international workshops on different aspect of diabetes in Endocrinology and Metabolism Research Institute.
- More than +20 educational campaigns for children have been organized with cooperation of Charity Foundation for Special Diseases.
- Establishment of Iranian Diabetes Academy. The Academy provides expert evidence at hearings, converses with governmental bodies, collaborates to establish national regulations, and develops position statements on diabetes issues. Furthermore, the Academy will make a platform for both national and international fundraising activities to strengthen research, research training and educational activities in the field of diabetes. More details about the academy is available via http://ida.tums.ac.ir

A.3. Activities on Diabetes Management
- Developing Diabetes Roadmap in collaboration with Ministry of Health
- Establishment of a system for registration of diabetic patients on a nationally inclusive database and provision of individualized health services to diabetic patients
- Designing an easy to access trilingual website for increasing public knowledge
- Representative of International Working Group on the Diabetic Foot in MENA Region
- Establishing a Diabetic Foot Care Specialty Ward in Dr. Shariati Hospital, Tehran, Center of Iran
- Establishing Specialty and Subspecialty Diabetes, which is consisted of clinical, diagnostic, and research units and so far the records of +32000 patients have been proliferated in the EMRI's clinics. As a national model, the Ministry of Health and Medical Education (MoHME) is now encouraging medical universities to establish such infrastructures.
What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
Participation in the WHO Global Diabetes Compact Forum is an excellent opportunity to raise awareness of the escalating health threat posed by diabetes at both the EMRO region and country levels. It’s also an occasion to link with worldwide efforts of international agencies, nongovernmental organizations, governments and the community. EMRI, being re-assigned as the WHO Collaborating Center in “Research and Education on Management of Diabetes and Osteoporosis” aims to be in the vanguard of combating these diseases locally, regionally, and internationally. The institute is a leading body in country which is involved in many diabetes advocate activities to raise awareness, influencing policy, and providing quality management service to patients with diabetes.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
USA sanctions on Iran had resulted lack of reusable insulin pens in a specific period during the COVID-19 pandemic. Although there are humanitarian exceptions to sanctions for the sale of food and medicine to Iran, the widespread use of sanctions against Iranian banks has complicated procurement efforts. To tackle the shortage, the ministry of health appointed some selected centers, including EMRI to distribute pens of insulin to patients through registration.

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy
As a result of efforts made by senior research staff at the Institute, several national documents including National Action Plan for the Prevention and Control of Non-Communicable Diseases and Related Risk Factors in the Islamic Republic of Iran (2015-2025) and National Diabetes Action Plan were developed and appraised by WHO former Director General Dr. Margaret Chan. EMRI strive to build on existing partnerships and build new collaborations in order to ensure that our research is influencing policy and practice in Iran and beyond.
Some of the EMRI’s recent prominent research on diabetes with national impacts are:
- National survey of NCD risk factors 2020; WHO STEPwise approach to surveillance (STEPs)
- National and sub-national study of burden of diseases, accident and injuries and risk factors (NASBOD)
- Population-based study on diabetes care in Iran (DiaCare)
- Behvarz Health Study
- Adaptation of IWGDF Guidance on prevention and Control of Diabetic Foot in Iranian Population
• Development of clinical guidelines on diabetes

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation

EMRI has made significant contributions in terms of promotion of health and wellbeing of patients with diabetes through innovative approaches. This interdisciplinary approach has led to 8 well-grounded patents and 14 research-based products several such as devices for measurement of glucose in the saliva, herbal-based medication diabetic foot, herbal mixture to treat patients with type 2 diabetes mellitus, and application of plasma irradiation for treatment of diabetic foot ulcer.


VISIT is the first Iranian Population Health Data Visualization System. It is a comprehensive online database which contains several health information platforms. Provincial distribution of non-communicable diseases (including diabetes) and mortality rate for each are available. VIZIT can eliminate cost of reporting, increase accessibility to health information, maximizes the effectiveness of projects’ results by creating dynamic reports.

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?

Evidence implies that patients with diabetes are at a higher risk of severe disease or death due to COVID-19 than individuals without diabetes. In Iran, like other countries, most risk assessment, screening, diagnostic, and management services for NCDs, including diabetes have been suspended and many people with diabetes have not received the treatment and medication they need since the onset of the COVID-19 pandemic.

In addition, as part of the social responsibility, amid the COVID-19 Pandemic, the institute has been engaged in a number of projects in collaboration with the Ministry of Health and Medical Education (MoHME), among which are:
• Design of an application to track COVID-19 epidemic prevention, management and control
• Evaluation of diabetes care, nutrition changes and nutritional needs in diabetes patients during COVID-19 pandemics
• Telehealth for fighting the novel COVID-19 virus: review of activities on Diabetes and Osteoporosis management in outbreak
• Evaluation of mental health as well as physical activity in patients with diabetes during COVID-19 pandemics
What is the mission of your organization?
To collaborate with WHO in the development of “diabetes prevention and control program” and its implementation in Asia-Pacific countries
To assist WHO in training doctors and nurses in the Western Pacific Region for improving the skills of management of diabetes

Describe the type of work your organization/ entity does in the field of diabetes:
At the request of WHO adapt the general WHO and International Working Group on Diabetic Foot guidelines on prevention of amputations for use in East Asia and Western Pacific region

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
We have contributed to raise the healthcare providers’ skills of management of diabetic foot problems in WPR in order to reduce amputation collaborating with WHO. We would like to continue to contribute it with WHO.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
We are making the regional guidelines of Diabetic Foot Problems with the counterparts in Asia-Pacific countries.

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy
We are making the regional guidelines of Diabetic Foot Problems prevention of diabetic foot) with the counterparts in Asia-Pacific countries.

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation
No information given.
Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care? We are asked by the local governments to join the infectious teams to treat COVID-19 patients (especially in terms of the management of blood glucose). All of our staffs are treating COVID patients in addition to treating diabetic patients without COVID-19. Our workloads are much more than before the outbreaks. However, we recognize that WHO global diabetes compact is very important for the people with diabetes and we would like to contribute it as much as possible as one member of WHOCC.

**Participant Profile – World Diabetes Foundation**

**Website:** [www.worlddiabetesfoundation.org](http://www.worlddiabetesfoundation.org)

**What is the mission of your organization?**
To alleviate human suffering related to diabetes and its complications among those in greatest need.

**Describe the type of work your organization/ entity does in the field of diabetes:**
World Diabetes Foundation (WDF) has since 2002 donated approximately USD 10 million on average every year to projects and programmes in LMIC contexts with an aim to prevent and control diabetes. Over the past decade and in accordance with the global health agenda, WDF has increased its support to integrated NCD response i.e., integrating diabetes care into e.g. hypertension/CVD control area, TB programmes, or maternal care. In recent years WDF has scaled up its grants and also prioritised more actively in global advocacy and with the engagement in the WHO Global Dialogue on Partnerships for Sustainable Financing of NCD Prevention and Control (2018) as a highlight.

**What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?**
WDF already supports the WHO Global Diabetes Compact directly and seeks to scale up this support and with a constant focus on country level implementation yet at the same time engaging in advocacy efforts at regional and global levels. Through the participation it is the hope that WDF will be able to collaborate with other agencies whereby efforts and investments can converge and build synergy and hence speed up implementation of national NCD responses across LMICs worldwide and as guided be the workstreams and targets of the Global Diabetes Compact.
Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.

WDF will increase its efforts to support broader health care supply chain management in LMIC contexts whereby hopefully essential NCD medicines and necessary supplies and basic equipment can be stronger incorporated into national supply chain and logistics. In terms of health technology it is important to note that in 2021 WDF established an entire new department entitled 'Digital Health Solutions' with the exact purpose of increasing WDF’s support to the promotion and utilisation of health technology within diabetes care.

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy

As part of WDF’s new strategy 2021-2025 prevention of diabetes and other NCDs will be given more priority and with specific focus on obesity, youth and women. In terms of health promotion and literacy it is observed that through its larger national NCD response partnerships these areas are a key component and often linked to community health support and engagements with civil society.

Please share any news, work, or events your organization is doing or plans to do regarding research and innovation

Through its expanded engagements with national NCD responses in LMIC contexts, WDF has embarked on a gradual prioritisation of research and operational research (implementation research) into the collaborative frameworks, preferably through integrated partnerships with national academic institutions. Hence, it is the aspiration that advanced monitoring and data collection will be strengthened and hence assist national health authorities and the international community in assessments of impact and efficiency etc.

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?

WDF as philanthropy based in Denmark has not been affected in terms of grant giving operations, in fact, WDF grants have increased so far during the COVID 19 pandemic. However, in many occasions have our grant implementing partners on ground in LMIC countries worldwide requested to adjust their activities to respond to the pandemic, recalling that people with NCDs have been most severely exposed to the COVID infection.
What is the mission of your organization?
• Connect and lead the cardiovascular disease community
• Translate science into policy
• Stimulate and catalyse the exchange of knowledge

Describe the type of work your organization/ entity does in the field of diabetes:
People with diabetes are two to three times more likely to develop a cardiovascular disease (CVD). Preventing CVD among people living with diabetes became one of the main focuses of the World Heart Federation in 2018 where in partnership with the International Diabetes Federation (IDF) an expert writing group assembled to develop the WHF Roadmap for prevention of CVD among people living with diabetes. The Roadmap is a key reference document for anyone involved in the planning, organisation, implementation and monitoring & evaluation of approaches related to CVD prevention in people living with diabetes. It outlines a vision of an ideal pathway of care, potential roadblocks along this pathway, and proposed solutions, with examples from practice. It draws Roadmap draws on the expertise of diabetes expert clinicians, researchers, implementation science experts and people with lived experience from around the world. It presents an integrated approach to patient care, involving the patient, healthcare system and health policy perspective. In an effort to implement the Roadmap at the local level, the WHF has convened several Roundtables on CVD and diabetes, in Brazil, Saudi Arabia, China, Mexico and Sweden.

What does your organization hope to achieve through participation in the WHO Global Diabetes Compact Forum?
WHF strongly believes in heart health for all and people who are diagnosed with diabetes should have access to equitable, comprehensive, affordable and quality treatment and care. WHF’s participation will encourage a dialogue around the strategies to prevent CVD in people living with diabetes with focus on both lifestyle management and risk factor interventions.

Please share any news, work, or events your organization is doing or plans to do regarding access to insulin and health technologies associated with diabetes.
No information given.

Please share any news, work, or events your organization is doing or plans to do regarding prevention, health promotion and health literacy
No information given.
Please share any news, work, or events your organization is doing or plans to do regarding research and innovation
No information given.

Have the stakeholders you represent been impacted by the COVID-19 pandemic, particularly with respect to access to insulin, diabetes supplies and other elements of diabetes care?
No information given.